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The aims of this study were to investigate the utilization, adherence, and effectiveness 
of 17-  hydroxyprogesterone caproate (17-OHPC) for patients with a history of preterm 
birth (PTB). A retrospective cohort study was conducted using 2012-2017 data from the 
Decision Recourses Group (DRG) database. The first diagnosis of high-risk pregnancy was 
the index date. A 6-month pre-index period was applied, and the patients were followed to 
delivery. Descriptive statistics, chi-square tests, and logistic regressions were used for data 
analysis. 
A total of 23,911 patients met criteria, with 2,051 (8.58%) having > 1 claim for 17-
OHPC. Patients with commercial insurance were more likely to use 17-OHPC compared with 
Medicaid patients (p<0.0001); and patients residing in the Southwest were more likely to use 
17-OHPC compared with patients residing in other areas of the U.S. (p<0.0001). Of the 2,051 
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women prescribed 17-OHPC, 407 (19.84%) were adherent using our baseline definition of 
adherence. No association was found between patients’ adherence rates and their demographic 
or clinical characteristics.  
Older patients aged 30-35 and aged >35 were 28% (OR=0.72, 95% CI=0.64-0.79) and 
34% (OR=0.66, 95% CI=0.59-0.74) less likely to have PTB, respectively, than patients aged 
<25; patients residing in the Southeast area were 12% less likely to have PTB (OR=0.64, 
95% CI=0.54-0.75) than Northeast patients; patients with hypertension were 15% (OR=1.15, 
95% CI=1.02-1.29) more likely to have PTB, than patients without hypertension; patients 
with a CCI score of 1, 2, or >3 were 10% (OR=1.10, 95% CI=1.01-1.20), 26% (OR=1.26, 
95% CI=1.14-1.41), and 35% (OR=1.35, 95% CI=1.17-1.56) more likely to have PTB, 
respectively, than patients with a CCI score of 0. After controlling for covariates, the 
incidence of PTB was not found to be associated with utilization of (p=0.44) or adherence to 
17-OHPC (p=0.14). The use of 17-OHPC was not associated with the incidence of diabetes 
(p=0.21). However, the use of 17-OHPC was shown to be associated with a lower incidence 
of hypertension (p=0.01). 
In conclusion, 17-OHPC use was low (<10%), adherence was low (<20%), and there 
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Chapter 1 Introduction 
1.1 Definition and Classification 
Preterm birth (PTB) is also known as premature birth. The World Health Organization 
(WHO) defines PTB as “babies born alive before 37 weeks of pregnancy are completed,” based 
on gestational age, which is a measure of pregnancy age.1 It is usually estimated by menstrual 
history, clinical examination of uterus size, and ultrasound biometric measurement.2 
Gestational age plays an essential role in predicting prenatal development events and 
estimating the date of delivery.3 According to gestational age, PTB can be stratified into three 
sub-types. When the gestational age is less than 28 weeks, it is treated as ‘extremely preterm.’ 
‘Very preterm’ occurs between 28 and 32 weeks. If babies are born between 32 and 37 weeks, 
it is considered a ‘moderate to late preterm’ birth.1 In addition, early term, full term, late term, 
and post term take place between 37 0/7 and 38 6/7 weeks, between 39 0/7 and 40 6/7weeks, 
the 41st week, and after 42 weeks, respectively.4  
PTB can also be categorized by the obstetric etiological precursors, in which PTB 
includes spontaneous preterm birth (SPTB) and medically indicated PTB.5,6 Medically 
indicated PTB refers to delivery for maternal or fetal indications, which accounts for one-third 
of PTBs,7,8 and occurs because of physicians’ interventions—either inducing the labor or 
performing a pre-labor cesarean delivery.6,9 SPTB is the most common type of PTB (66%), 
occurring when a woman goes into labor with intact membranes (40-45%) or preterm 
premature rupture of membranes (PPROM) (25-30%).6-8,10 The rates of different types of PTB 




Figure 1. 1 U.S. Preterm Birth Rates for Different Types of PTB from 1989 to 2000 
 
Source: Ananth CV, Joseph KS, Oyelese Y, et al. Trends in preterm birth and perinatal mortality among singletons: 
United States, 1989 through 2000. Obstetrics & Gynecology 2005;105(5):1084-1091.11 
Recurrent PTB is another subgroup of PTB based on the previous number of PTBs. It 
refers to “more than one delivery before 37 gestational weeks occurring for the same woman,” 
which can be either recurrent indicated PTB or recurrent SPTB.12 A summary of different types 
of PTB and standards of classification are listed in Table 1.1. 
Table 1. 1 Classification of Preterm Birth 
1.2 Epidemiology of Preterm Birth 


























Classification Standards PTB Types Operational Definitions 
Categorized by gestational 
age 
Extreme preterm Gestational age < 28 weeks  
Very preterm Gestational age  28 and < 32 
weeks  
Moderate to late preterm Gestational age  32 and < 37 
weeks 
Categorized by obstetric 
etiological precursors 
Medically indicated PTB Occurs because of physicians’ 
interventions 
Spontaneous PTB Occurs spontaneously (no 
intervention) 
Categorized by number of 
prior PTBs 
Recurrent PTB More than one PTB occurring for 
the same woman 
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approximately 15 million preterm infants born each year.1 Globally, the leading cause of death 
of children under 5 years and long-term disability is PTB complications, which result in 
approximately 1 million children dying every year.13 Three-fourths of perinatal mortality and 
over 50% of long-term morbidity are due to PTB.8 The survival rate of preterm infants born at 
22 weeks is about 6%, and rises to 72% at 25 weeks.14 In addition to low survival rate, since 
some important organs of preterm infants (e.g., brain, lungs, and liver) are still in the process 
of developing, these infants face a high risk of multiple health problems, such as cerebral palsy, 
delays in development, sensory deficits, hearing problems, and respiratory illnesses.15,16  
Even though PTB is a global issue, its prevalence varies across the world, ranging from 
5% to 18% across 184 countries.1 PTB occurring in Africa and South Asia accounts for more 
than two-thirds of global PTB, with estimated PTB rates of 11.6% and 11.4%, respectively.1,15 
This problem is more common in low-income countries. The three countries with the highest 
rates of PTB per 100 live births are Malawi (18.1%), Comoros (16.7%) and Congo (16.7%) 
(2018).1,17 Among countries with the greatest number of PTBs, India, China, and Nigeria are 
ranked in the top three (2018).1 Compared to developing countries, the incidence rates of PTB 
for developed countries are relative low. Estimated PTB rates are reported to be 5-9 % for 









Figure 1. 2 Top 10 Countries with the Greatest Number of Preterm Births 
 
Source: WHO. Preterm birth: Key facts. 2018; http://www.who.int/en/news-room/fact-sheets/detail/preterm-
birth1 
The United States has the highest PTB numbers among developed countries, and ranks 
6th of countries with the greatest number of PTBs.1 It is also the only developed country on the 
top 10 list (See Figure 1.2).18 In the late 20th century, the PTB rate of the U.S. showed a steady 
rising tendency, increasing from 9.5% in 1981 to the peak of 12.8% in 2006.18-20 Since then, 
the PTB rate has been declining. However, a recent report published by the March of Dimes, a 
nonprofit organization concerned with the health of mothers and babies, presented a rise in the 
U.S. PTB rate from 9.6% in 2015 to 9.9% in 2017, with the highest PTB rate of 13.6% in 















Top 10 Countries with the Greatest Number of Preterm Births
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Figure 1. 3 United States Preterm Birth Rate, 2007-2017 
  
Source: Adapted from March of Dimes. 2018 Premature Birth Report Card United States. 2018. 
https://www.marchofdimes.org/materials/PrematureBirthReportCard-United%20States-2018.pdf 21 
 
1.3 Economic Burden of Preterm Birth 
The Institute of Medicine (IOM) (2007) estimated the annual societal cost attributed to 
PTB in the U.S. as $26 billion ($US 2005).22 Disability-specific lifetime medical costs, 
educational costs, and lost productivity costs were taken into consideration for this 
estimation.20 Medical costs for each preterm child was estimated to be about ten times greater 
($32,325) than that for term children ($3,325) during the first year of life,22 which is similar to 
estimates in England and Wales in 2006 ($35,471).23 The estimates for ‘very preterm’ and 
‘extremely preterm’ infants were even higher, at $95,760 and $146,847, respectively.23 Grosse 
et al. (2017) used private health insurance claims data during 2013 to calculate first-year 
expenditures for employer-sponsored health plans for preterm born infants. They reported that 
7.7% of insured preterm infants accounted for 37% of the $2.0 billion spent on the care of 
infants, and PTBs cost the included plans an extra $600 million during the infants’ first year of 






















2007-2017 United States Preterm Birth Rate
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sponsored plan expenditures of $6 billion for preterm infants. In addition, the mean 
expenditures for preterm infants with major birth defects ($226,840) is 3.5 times greater than 
full-term infants with major birth defects.24  
Jacob et al. (2017) also compared the health care costs associated with early preterm, 
late preterm, and full-term birth based on 2011-2012 claims data from a German health 
insurance company. They found that the average costs of early preterm, late preterm, and full-
term infants in the first year after birth were 74,009 EUR, 8,565 EUR, and 1,590 EUR, 
respectively. Cost differences tended to decrease in the second and third year after birth, though 
the ambulatory treatment costs did not decrease for early preterm births but decreased for late 
preterm and full-term births.25  
In terms of hospitalizations related to PTB, the average length of hospital stays for 
preterm infants after birth is 13 days, which is approximately eight times longer than the 
average 1.5 days for term babies.22 Russell et al. (2007) estimated the cost of hospital 
admissions for preterm infants in the U.S. accounted for about half of the costs (47%) of all 
infant hospitalizations and more than one-fourth (27%) of all pediatric stays.26 According to 
McLaurin et al.’s study (2009), late preterm infants had 12.6 times higher mean expenditures 
for the hospitalization than full-term infants.27 Stephen et al. (2016) used birth data of Australia 
from 2001 to 2011, finding that the mean costs per hospitalization were $26,800, $9,850, and 
$4,980 for infants born at 24-27, 28-31, and 39-40 weeks of gestation, respectively.28 Given 
the lack of more recent studies on different types of costs related to PTB, new studies are 
warranted.  
The sizable cost differences for preterm infants are mainly due to neonatal intensive 
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care, infant complication treatment costs, and ongoing healthcare costs.17,23 According to a 
study in England and Wales (2009), costs borne during the neonatal period represented 92.0% 
of the incremental cost per preterm survivor.23 Simultaneously, in order to take care of the 
mother and the preterm baby, more family member support is needed, which results in 
decreased productivity.17 In the long run, it is possible that families also face the responsibility 
to care for their disabled children with increased day-care costs and costs for nutrition and 
alternative therapies.10,29 The economic effects may also extend to the survivors’ possible lower 
education level, lower income, and increased need for social support.30 
1.4 Signs and Symptoms 
In most cases, preterm labor can be asymptomatic and unexpected. Some warning signs 
of preterm labor are similar to regular labor, such as uterine contractions every 10 minutes or 
more often, changes in vaginal discharge (can be an increase in amount, or a change in color), 
changes in urinary habits (increased frequency or burning sensation), pelvic pressure, low and 
dull backache, menstrual-like cramps, or abdominal-intestinal cramps with or without 
diarrhea.31,32 Some clinical predictors of PTB include initial cervical dilatation of 3cm or more, 
cervical effacement of 80% or more, vaginal bleeding, and ruptured membranes.33 Since the 
initial symptoms and signs are mild and can happen during a normal pregnancy, it is difficult 
to predict PTB.33  
1.5 Risk Factors  
PTB is a multi-factorial syndrome, which may be driven by multiple mechanisms.8 No 
definite causal pathway of PTB has been established, but a number of risk factors have been 
reported. By identifying risk factors of PTB, healthcare providers may target high-risk pregnant 
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women and provide corresponding prevention or treatment approaches. Therefore, gathering 
more insights about risk factors can help to investigate the exact mechanisms of PTB in the 
future.  
Several ways of clustering risk factors were reported by different researchers. Moutquin 
et al. categorized risk factors by types of PTB, including risk factors of medically induced PTB, 
PPROM, and SPTB.5 Alleman grouped them into chronic stresses, acute stressors, and 
underlying genetic risk.10 Goldernberg et al. categorized them into maternal risk factors and 
fetal risk factors. Maternal risk factors include maternal demographic characteristics, 
pregnancy history, pregnancy characteristics, and biological and genetic markers.8 This paper 
mainly focuses on introducing risk factors related to SPTB, despite some risk factors shared by 
more than one type of PTB. 
1.5.1 History of Preterm Birth 
Having a history of PTB is one of the strongest risk factors of SPTB. A systematic 
review and meta-analysis of literature from 1948 to 2017 concluded that the absolute risk of 
PTB recurrence was 30%.34 Bloom et al. found the PTB recurrence rate was also related to the 
number of previous PTBs, with rates of 16%, 41%, and 67% for those with 1, 2, and 3 previous 
PTBs.35 
According to studies from different countries, pregnant women with a history of PTB 
are approximately 2 to 5.7 times more likely to have a subsequent SPTB.35-40 Mercer et al. 
reported that compared to women without prior PTB, women with prior PTB had a 2.5-fold 
increased risk of SPTB for their current gestation.40 By conducting a retrospective study based 
on data from five Japanese perinatal centers from 2008 through 2012, Yamashita et al. found 
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that a previous PTB had a twofold increased risk of SPTB (OR=2.26, 95% CI=1.19-4.30).37 
Based on U.S. data (Missouri), Ananth et al. reported that women who had a SPTB in their first 
pregnancy were three times more likely to deliver preterm spontaneously during the next 
pregnancy (OR=3.6, 95% CI=3.2-4.0).38 Leal et al. also reported similar results using a national 
population-based sample of Brazilian women (OR=3.74, 95%  CI=2.92-4.79).36 Carlini et al. 
investigated the risk factors for SPTB in northern Italy, and the results showed that previous 
PTB had a significant association with PTB (OR=5.7, 95% CI=2.5-12.9).39 Bloom et al. found 
women who delivered a singleton before 35 weeks were 5.6 times more likely to have recurrent 
PTB; the odds ratio for recurrent PTB with intact membranes was 7.9, and 5.5 with ruptured 
membranes.35 Prior early PTB (or very PTB) showed a more extreme increased risk for 
recurrent PTB. Moreover, there is research showing that gestational age of women with a 
second PTB is similar to that of their first pregnancy.38  
1.5.2 Black Race 
Generally, PTB rates are lower among east Asian, White, and Hispanic women, but 
higher in Black women, with the PTB rate for Black women ranging from 16-18%, compared 
to 5-9% for White women.8 U.S. birth data for 2017 shows that the PTB rates were 13.93% for 
Black women, 8.53% for Asian women, 9.05% for White women, 11.86% for American Indian 
or Alaska Native women, and 9.62% for Hispanic women.41 There have been many studies 
reporting that Black, African-American, or Afro-Caribbean women have a higher risk for 
recurrent PTB than other races, though the differences have not been adequately explained 
despite accounting for disparities in prenatal treatment, history of pregnancy, and other 
behavioral factors.8,42-45 Kistna et al. used the Missouri Department of Health’s maternally 
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linked database and found that Black women were approximate 4 times more likely to have 
recurrent PTB and earlier gestations than White women.42 Another cohort study using data 
from Georgia reported that African-American women were at higher risk of recurrent PTB than 
Caucasian women (13.4% vs 8.2%).43 TNF-2 and SERPINH1 are two candidate genes 
accounting for PTB in African-American women.18 However, in spite of similar carrier 
frequencies for the allele, African-American women (OR=2.5) still had a higher risk of SPTB 
than Caucasians (OR=1.6).46  
1.5.3 Short Cervical Length 
Cervical length refers to the length of the lower end of the uterus. Typically, the shorter 
the cervical length, the greater risk women face for SPTB.8,12 Compared to a cervix of normal 
length, it is more difficult for a short cervix to remain closed during pregnancy, which results 
in cervical insufficiency, defined as “the inability of uterine cervix to retain a pregnancy in the 
absence of contractions or labour.”12,47 The normal length of a cervix in a non-pregnant woman 
is 40mm to 50mm. But during pregnancy, the cervix will gradually soften, shorten, become 
thinner, and finally open when the body is ready to give birth.48 The normal cervical length is 
40-45mm at 16 to 20 weeks, 35-40mm at 24-28 weeks, and 30-35mm at 32-36 weeks.49 There 
is no consensus on the cut-off point of defining a sonographic short cervix.50 The definition of 
“short” cervix varies from 15mm to 30mm across different studies; however, clinically, 25mm 
is usually used to define a “short” cervix.47,50-54 In 1996, Iams et al. proposed that a shorter 
cervix may indicate a greater risk of SPTB. The results showed the relative risks of SPTB 
increased as the cervix length decreased (RRs= 3.79 for 30 mm, 6.19 for 26mm, 9.49 for 22mm 
and 13.99 for 13mm). 54  
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1.5.4 Low Maternal Body-Mass Index (BMI) 
Low pregnancy BMI and low pre-pregnancy BMI can both lead to an increased risk of 
SPTB; moreover, low maternal BMI is also related to low birth weight (r=0.157, p=0.041).55 
In a meta-analysis examining the relationship between maternal weight and the risk of PTB, 
the results showed the risk of SPTB was increased in underweight (BMI ≤ 20) women (adjusted 
RR=1.32, 95% CI=1.10-1.57).56 Low BMI can be an indicator of poor nutritional status of 
pregnant women. Thin women often consume less vitamins and minerals, resulting in low 
serum iron, folate, or zinc levels.57 Malnutrition increases a woman’s vulnerability to maternal 
infection and decreased blood flow.58  
1.5.5 Multiple Gestation 
Multiple gestation is one of the risk factors for PTB. Multifetal gestations only account 
for 2-3% of infants, but they are related to 10-20% of all PTBs.8 Nearly 50-60% of women 
with a twin gestation gave birth before the 37th week of gestation.6,59 Multiple gestation has an 
influence on both indicated and spontaneous PTB, with SPTB accounting for 70% of PTB in 
multiple births.60 As for the association between multiple gestation and recurrent PTB, there is 
no agreement if multiple gestation results in a higher risk of recurrent PTB. Menard et al. 
claimed that PTB in twin gestations was significantly associated with increased risk of PTB in 
a subsequent singleton pregnancy, with 19.6% of women who delivered preterm twins 
delivering preterm (before 37 weeks of gestation) in a subsequent singleton pregnancy 
(RR=2.87, 95% CI=1.02-8.09), and with 42% of subsequent singleton pregnancies delivered 
preterm for women who delivered twins before 30 weeks of gestation (RR=6.11, 95% CI=2.07-
18.02).61 In contrast, Bloom et al. reported a significant higher risk for recurrent PTB among 
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women who previously delivered a singleton preterm (OR=5.6, 95% CI=4.5-7.0), but not for 
those who previously delivered twins preterm (OR=1.9, 95% CI=0.48-8.14).35 
1.5.6 Other Risk Factors 
In addition to the above-mentioned risk factors, there are other factors associated with 
a higher risk of PTB. Prior cervical surgery, multiple dilatations, and uterine anomalies can 
also contribute to an increased risk of PTB.6 Regarding maternal demographic characteristics, 
age (<17 or >35 years), low education level, low socioeconomic status, single marital status, 
short inter-pregnancy interval, and genetics are related to an increased risk of PTB.6,8 
Furthermore, in addition to multiple gestations and short cervix, current pregnancy-related risk 
factors include prior surgery on the cervix (e.g., termination of pregnancy, spontaneous 
abortion), assisted reproductive techniques, vaginal bleeding, polyhydramnios or 
oligohydramnios, maternal comorbidities (e.g., hypertension, preeclampsia, diabetes, thyroid 
disease), mental health issues (e.g., stress, depression, anxiety), maternal nutrition status, 
infections (e.g., bacterial vaginosis, trichomoniasis, chlamydia, gonorrhea), inflammation, 
positive fetal fibronectin, and uterine contractions.6,10 Lastly, some adverse behaviors, like 
tobacco use, excessive alcohol consumption, and drug abuse, also increase the risk of PTB (See 










Table 1. 2 Risk Factors for PTB 
Classification Risk Factors 
Maternal demographics Age (<17, or >35 years) 
Race (Black) 
Low BMI 
Low education level 
Low socioeconomic status 
Single marital status 
Short inter-pregnancy interval 
Prior obstetric history Genetics 
Prior PTB 
Cervical surgery 
Current pregnancy characteristics Short cervix 
Multiple gestations  
Assisted reproductive techniques 
Vaginal bleeding 
Volyhydramnios or oligohydramnios 
Maternal comorbidities (e.g. diabetes, hypertension) 
Mental health issues (e.g. stress, depression) 
Poor nutrition status 
Infections 
Inflammation 





Excessive alcohol consumption 
Drug abuse 
Source: Adapted from Berghella V. Preterm birth: prevention and management. Chapter 4. P28. John Wiley & 
Sons; 2010.6 
 
1.6 Prevention of PTB 
Overall, there are three types of prevention—primary, secondary, and tertiary 
preventions. Primary prevention mainly involves preventing exposure to hazards, which may 
target prepubertal girls to educate them and optimize their health, women who plan to get 
pregnant to raise their awareness and maintain healthy lifestyles, and even men who are a 
sexual partner of targeted women. This education may involve: raising awareness of 
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significance of PTB; exercising and a healthy diet to arrive at an ideal BMI; ensuring adequate 
nutrition and using dietary supplementation (folate acid, vitamins, calcium, zinc, etc.) if needed; 
decreasing unplanned pregnancies; avoiding tobacco, alcohol, and illicit drug use; minimizing 
stress; preventing sexually transmitted infections; and limiting the number of embryos 
transferred during in vitro fertilization (IVF).6  
Different from primary prevention, secondary and tertiary prevention are easier to track, 
and effectiveness is more readily identified. Hence, healthcare providers and pharmaceutical 
companies put more emphasis on secondary and tertiary prevention strategies. The purpose of 
secondary prevention is to detect a disease early and prevent it. Receiving screening or 
predictive tests, such as physical examinations or ultrasonography examinations, fetal 
fibronectin (fFN) tests, or placental alpha macroglobulin-1 (PAMG-1) tests may be helpful in 
detecting abnormalities for an asymptomatic population.6  
Tertiary prevention focuses on women with signs or symptoms of preterm delivery. 
Several major tertiary prevention strategies of SPTB include the use of progesterone, cervical 
cerclage, tocolytics, and antibiotics. The choice of these different approaches is based on 
various risk factors that are identified. Progesterone supplementation has been shown to be 
effective for women with a history of SPTB or with a short cervix. Cervical cerclage is 
suggested to be implemented among women with a short cervix, which refers to putting a suture 
into or around the cervix in order to treat cervical insufficiency.62,63 Cerclage has also been 
shown to be effective for women with a history of SPTB.63 Tocolytic medications are used to 
suppress contractions when early labor begins and typically delay birth for 2 to 7 days.64 When 
a fetus is in immediate danger, tocolytics ought not to be administered. Tocolytics may also 
15 
 
serve as adjunctive therapy to progesterone and cervical cerclage.10 For women with symptoms 
of infections, corresponding antibiotics are suggested for PTB prevention. Antibiotic therapy 
has been shown to prolong the interval of time from membrane rupture to delivery for patients 
with PPROM.65 
In summary, PTB results in tremendous clinical and economic burden, and, thus, it is 
significant to investigate how to effectively prevent PTB. Among three types of prevention, 
tertiary prevention strategies have been involved in most research, because women usually go 
to see physicians when the symptoms of PTB appear, and the effectiveness of tertiary 
prevention is easier to measure. Simultaneously, tertiary prevention strategies are the most 
expensive, compared to primary and secondary prevention strategies, so it is important to 
evaluate their effectiveness. Since SPTB is the most common type of PTB (accounting for 2/3 
of PTBs), and progesterone supplements, as one of the main tertiary prevention strategies, was 
recommended for all women with history of PTB to prevent SPTB,66 more information about 





Chapter 2 Literature Review 
2.1 Progesterone and 17-Hydroxyprogesterone Caproate (17-OHPC) 
2.1.1 Introduction of Progesterone and 17-OHPC 
Progesterone, one of the progestogens in humans, is a natural sex steroid produced by 
the corpus luteum during the first trimester of pregnancy. It plays a crucial role in the 
maintenance of early pregnancy through 7 to 9 weeks of gestation. Subsequently, the corpus 
luteum begins to decrease in size and the placenta takes over progesterone production to 
support gestation and inhibit uterine activity.67-69 Progestin is usually mixed with progesterone, 
which is a synthetic analog of natural progesterone structure. Thus, strictly, 17- 
hydroxyprogesterone caproate (17-OHPC) is a synthetic compound, which is progestin rather 
than progesterone. However, some researchers categorize progesterone as synthesized and 
natural progesterone (or natural micronized progesterone).69,70 From this perspective, 17-
OHPC can be seen as a subtype of progesterone.  
A common abbreviation of 17-hydroxyprogesterone caproate is 17-OHPC or 17P. 
However, it is inaccurate to use 17P as the abbreviation for 17- hydroxyprogesterone caproate, 
since 17P is also the abbreviation of 17-hydroxyprogesterone, which is a natural steroid 
produced by the ovaries, and does not contain the caproate molecule.68  
2.1.2 Mechanism of Progesterone and 17-OHPC  
The molecules for natural progesterone and 17-OHPC are different, as are their 
mechanisms of action. Progesterone receptor A (PR-A) and Progesterone receptor B (PR-B) 
are two predominant forms of receptors that play important roles during pregnancy. Binding 
PR-B and progesterone will stimulate the transcription of genes that promote uterine relaxation; 
17 
 
and PR-A is a repressor of PR-B function, which is related to the onset of labor.71 Through 
mediation of PR-A and PR-B, progesterone exerts its action in “relaxation of myometrial 
smooth muscle, blocking of the action of oxytocin and inhibition of the formation of gap 
junctions between myometrial cells.”72 In another words, progesterone is helpful in reducing 
the contraction of myometrial muscles so as to maintain pregnancy. Progesterone also exerts 
an impact on anti-inflammation through the inhibition of monocyte chemoattractant protein-1 
(MCP-1).  
In contrast, the mechanism of 17-OHPC is not fully understood. Although one study 
found that 17-OHPC had some anti-inflammatory effects,73 compared to vaginal progesterone, 
17-OHPC does not appear to have a significant anti-inflammatory effect.74 Moreover, unlike 
progesterone, 17-OHPC does not have an effect on the myometrium or uterine contractions.65,71 
Nonetheless, the primary effect of 17-OHPC in preventing PTB seems to be on the cervix. 
Studies found 17-OHPC can delay cervical collagen degradation, and it is associated with less 
cervical shortening clinically.65 Still, the specific mechanism of 17-OHPC needs further 
exploration. 
2.1.3 Dosage Forms of Progesterone and 17-OHPC  
Progesterone supplements are available in the form of vaginal gel, vaginal suppository, 
oral capsule, and intramuscular injection. Natural progesterone can be supplied in any of the 
first three forms, while synthesized progesterone is only supplied as an intramuscular 
injection.70 The dosage, use interval, and duration of effects also differ for the various dosage 





Table 2. 1 Route, Dose, Interval and Duration of Different Progesterone Supplement 
Therapy  
Drug Type Route Dose Interval Duration References 
17-OHPC Intramuscular 
injection 
250mg Weekly Start 16-20 







Vaginal gel 45mg (4% gel),  
90mg (8% gel) 
 
Daily Start 18-24 
weeks of 
gestation, until 








Daily Start 16-24 
weeks of 
gestation, until 
34-36 weeks of 
gestation 
79-83 
Oral capsule 200mg,  
400mg 
Daily Start 18-24 
weeks of 
gestation, until 
33-36 weeks of 
gestation 
84,85 
Source: Adapted from Choi SJ. Use of progesterone supplement therapy for prevention of preterm birth: review 
of literatures. Obstetrics & Gynecology Science. 2017;60(5):405-420. 70 
2.1.4 Branded vs. Compounded 17-OHPC  
Before the 1990s, 17-OHPC was marketed under the brand names DelalutinTM and 
HydrogestTM. However, due to controversy of the effectiveness in preventing PTB, these 
products were discontinued. After approximately 20 years of development, the U.S. Food and 
Drug Administration (FDA) approved the use of 17-OHPC in preventing recurrent SPTB under 
the brand name MakenaTM in 2011.65 In addition to MakenaTM, compounded 17-OHPC is 
available in U.S. pharmacies. There are only a few studies investigating the effectiveness of 
compounded 17-OHPC, with results showing administration of the compounded version of 17-
OHPC to be safe and effective,86 and no significant difference in the PTB rate was found 
between the branded and compounded drug.87 Even though the use of compounded 17-OHPC 
is not recommended by the FDA, there is no enforcement against pharmacies that provide 
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compounded alternatives due to patient access concerns and special medical needs.65,71 
Moreover, under section 503A of the Federal Food, Drug, and Cosmetic Act, “a pharmacist 
may not compound regularly or in inordinate amounts any drug products that are essentially 
copies of Makena.”88 
2.2 Clinical Evidence on Efficacy of 17-OHPC in Preventing SPTB 
Since the 1950s, progestin supplementation has been studied as a means to prevent 
PTB.65 Goldstein et al. (1989) conducted a meta-analysis to evaluate the efficacy of 
progesterone and other progestogenic agents. This meta-analysis included 15 randomized 
control trials (RCTs) published between 1975 and 1980, with the conclusion that progestogens 
having no impact on any pregnancy outcomes, which was measured by rate of PTB and rate of 
miscarriage.89 However, since different forms of progestogenic agents may have different 
effectiveness in the prevention of SPTB, Keirse et al. (1990) conducted a meta-analysis 
assessing effectiveness of 17-OHPC with stricter inclusion criteria (e.g., using data from 
placebo-controlled trials). They concluded there was no support for the role of 17-OHPC in the 
prevention of miscarriage, but it may be effective for PTB prevention (OR=0.50, 95% CI=0.30-
0.85).90 
A noteworthy large multicenter double-blind placebo-controlled trial was conducted by 
Meis et al. (2003) with the National Institute of Child Health and Human Development 
Maternal-Fetal Medicine Units Network (NICHD) to examine the efficacy of 17-OHPC in 
preventing recurrent SPTB. The study included 463 women, with 310 (67.0%) receiving 
weekly injections of 250mg of 17-OHPC and 153 (33.0%) receiving a placebo until delivery 
or 36 weeks of gestation. Results showed the incidence of delivery before 37 weeks of gestation 
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was 36.3% in the treatment group versus 54.9% in the placebo group (RR=0.66, 95% CI=0.54-
0.81), which indicated that injections of 17-OHPC may significantly reduce the risk of 
recurrent SPTB.75 This conclusion was similar to one provided by Saghafi et al. in 2011. By 
analyzing 100 women with a history of PTB, they found weekly administration of 17-OHPC 
was significantly associated with a decrease in preterm delivery (p=0.011) and improvement 
in neonate birth weight  (p=0.02).76  
However, the efficacy of 17-OHPC is still a controversial topic for pregnant women 
with different risk characteristics. Combs et al. (2015) tested the effectiveness of 17-OHPC in 
women with preterm premature rupture of membranes (PPROM). The primary outcome was 
birth at a favorable gestational age (32 to 34 weeks), but only 3% of the treatment group 
achieved this outcome, and there was no significant difference between the treatment and 
control groups (p=0.18).91 Winer et al. (2015) found that among women with a cervical length 
less than 25mm and a history of PTB, cervical surgery, or uterine malformation, 17-OHPC 
showed no impact in prolonging pregnancy. When varying the cut-off definition to 32, 34, or 
37 weeks, again no significant differences were found.92 The efficacy of 17-OHPC may also 
vary according to the weight of women. Heyborne et al. (2015) performed a secondary analysis 
from Meis’s trial75 to examine if body mass index (BMI) modified the effectiveness of 17-
OHPC. Results showed 17-OHPC is only effective for women with pre-pregnancy BMI < 30 
kg/m2 (RR=0.54, 95% CI=0.43-0.68). When the researchers used only maternal weight instead 
of BMI, 165lb was the observed threshold above which 17-OHPC was not effective.93  
None of above studies included women with multiple gestation, which is known to 
increase the risk of PTB. However, there are studies focusing on exploring the efficacy of 17-
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OHPC for women with multiple gestation. Awwad et al. (2015) selected 288 women with twin 
pregnancies to carry out a RCT. Results indicated injection of 17-OHPC did not reduce PTB 
in twin pregnancies. Nevertheless, as the secondary outcome, neonatal morbidity was found to 
be significantly lower in the 17-OHPC group (19.1%) than the placebo group (30.9%) (OR = 
0.53, 95% CI = 0.31-0.90), and the birthweights of neonates were increased.94 Furthermore, 
two studies reported that among women with triplet pregnancies, gestational age at delivery 
and neonatal morbidity was not influenced by 17-OHPC.95,96 
The concentration of 17-OHPC may also influence its effectiveness. Caritis et al. (2014) 
used blood samples obtained from 315 women with a SPTB. Their plasma concentrations of 
17-OHPC ranged from 3.7 to 56ng/ml, and low plasma 17-OHPC concentrations were 
associated with an increased risk of SPTB. Women with the lowest quartile plasma 
concentrations had a significantly higher risk of SPTB (p=0.03).97 However, a prospective 
cohort study reached different conclusions—no significant difference was found in median 17-
OHPC levels between women who delivered before 35 weeks and after 35 weeks of gestation.98 
A weekly injection of 250mg 17-OHPC is the regulated dosage as specified by Makena’s 
manufacturer,99 and this dosage was used in previous studies. However, no data suggest a dose 
adjustment based on patient BMI or any other patient-specific indexes, nor are there published 
guidelines that specify the optimal dose of 17-OHPC. Genotype may also play a role in the 
efficacy of 17-OHPC. Manuck et al. (2017) claimed that human progesterone receptor gene 
polymorphisms can alter the clinical efficacy of 17-OHPC in the prevention of PTB.100  
It is also noteworthy that a confirmatory phase 3B RCT of 17-OHPC versus vehicle for 
prevention of PTB [“Progestin’s Role in Optimizing Neonatal Gestation (PROLONG),” 
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NCT01004029] completed in 2018, which was initiated in 2009 and funded by AMAG (the 
manufacture of “MakenaTM”), and it did not demonstrate a statistically difference in the 
incidence of PTB between the treatment and placebo group (p=0.72).101,102 To date, no 
manuscript has been published based on this clinical trial. Since more than 75% of patients 
were enrolled outside the U.S., and mainly from Eastern European countries, Julie Krop, 
AMAG’s Chief Medical Officer said, “In light of the recent findings and the inconsistencies 
with prior clinical evidence, we plan to conduct additional subgroup analyses of the 
PROLONG data, particularly focusing on patients at the highest risk of preterm delivery and 
the subset of patients enrolled in the U.S.”102  
2.3 Clinical Evidence on Efficacy of Vaginal Progesterone in Preventing SPTB 
The efficacy of vaginal progesterone in reducing PTB rates and improving neonatal 
outcomes among high-risk pregnant women, either with a history of PTB or with a short cervix, 
has been assessed by numerous RCTs which compared vaginal progesterone to placebo. The 
PTB rates in patients with vaginal progesterone (no matter in the form of gel, suppository, or 
capsule) ranged from 2.7% to 19.2% and differed significantly with placebo groups, with PTB 
rates ranging from 18.5% to 34.3%.79,81 O’Brien et al. (2007) found that vaginal progesterone 
showed no effect on women with a history of PTB,77 but they used a PTB cut-off of 32 weeks, 
where other studies selected 34 or 35 weeks, which may explain the difference in results.   
In addition to comparisons with placebo, the efficacy of vaginal progesterone was also 
compared to 17-OHPC injections in reducing SPTB rate by a number of studies. Maher et al. 
(2013) compared vaginal gel to 17-OHPC among women with a history of PTB and without a 
short cervix on the SPTB rate at 34 weeks, 32 weeks, and 28 weeks. For all three cut-off points, 
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vaginal progesterone gel was significantly more effective in reducing the rate of PTB. The PTB 
rates(< 34 weeks) for the vaginal gel group and the 17-OHPC group were 16.6% vs. 25.7% (p= 
0.02).78 However, in Bafghi et al.’s study in 2015 (which included women either with a history 
of PTB or a short cervix),80 Norman et al.’s study in 2016 (which included women either with 
a history of PTB or a short cervix),83 Pirjani et al.’s study in 2017 (which included women with 
a short cervix only)81 and Elimian et al.’s study in 2016 (which included women with a history 
of PTB only),103 no significant differences between vaginal progesterone and 17-OHPC were 
identified for the rate of SPTB or neonatal outcomes. 
Based on various results from RCTs, researchers also conducted systematic reviews and 
meta-analyses comparing vaginal progesterone and 17-OHPC outcomes. A meta-analysis was 
conducted by Saccone et al. (2017) to compare vaginal progesterone with 17-OHPC for 
prevention of recurrent SPTB in singleton gestations. No significant differences were identified 
in the rate of SPTB < 37 weeks, < 28 weeks, and < 24 weeks. However, women in the vaginal 
progesterone group had a significantly lower rate of SPTB < 34 weeks and < 32 weeks. In 
addition, a lower rate of neonatal intensive care unit admission was observed in the vaginal 
progesterone group. Nevertheless, only three studies were included in the analysis, and the 
authors also pointed out the quality level of the studies was low, so the results may not be 
robust.104 Romero et al. (2014) also published a review on the comparison of the two drugs. 
They concluded that vaginal progesterone is effective in women with a short cervix both with 
and without a prior history of PTB; while 17-OHPC is only effective for women with a prior 
PTB, but not for women with a short cervix.105  
24 
 
2.4 Guideline on the Use of 17-OHPC in Prevention of SPTB 
Based on the results from clinical trials on efficacy of 17-OHPC and vaginal 
progesterone, several guidelines on use of 17-OHPC and/or vaginal progesterone have been 
published. In 2012, The American College of Obstetricians and Gynecologists (ACOG) 
published a guideline on prediction and prevention of PTB. As for the clinical recommendation 
for management of women with a singleton pregnancy and a prior spontaneous preterm 
delivery, the guideline suggests “offering progesterone supplementation starting at 16-24 
weeks of gestation to reduce the risk of recurrent spontaneous preterm birth.” In this context, 
the progesterone supplementation referred to 17-OHPC (250mg weekly injections), vaginal 
progesterone suppository (100mg daily), vaginal progesterone gel (90mg daily), and 
micronized vaginal progesterone capsules (200mg daily). However, for asymptomatic women 
with a short cervix who do not have a history of PTB, only cerclage and vaginal progesterone 
were recommended. On the other hand, for women with a singleton pregnancy who did not 
have a prior PTB and have normal or unknown cervical length, progesterone treatment is not 
recommended. For women with multiple gestations, currently, no available approach is found 
to be effective in reducing their risk of PTB.106  
The Society for Maternal-Fetal Medicine (SMFM) committee also published a 
guideline in 2017 on the prevention of SPTB in women with a singleton pregnancy. For this 
particular group of women, weekly injections of 250mg 17-OHPC were recommended, starting 
at 16-20 weeks until 36 weeks of gestation or delivery. However, inconsistent with ACOG’s 
guideline, vaginal progesterone was not recommended as a substitute for 17-OHPC.66 
Another guideline published in 2011 for the management of SPTB is endorsed by the 
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European Association of Perinatal Medicine (EAPM). Similar to ACOG’s guideline, 
microionized progesterone and 17-OHPC are recommended for asymptomatic women 
presenting with a prior history of PTB. However, the initiation time of injection is not specified 
in this guideline. In multiple pregnancies, neither microionized progesterone nor 17-OHPC was 
recommended. In spite of this, it is worth noting that in contrast to the ACOG’s guideline, in 
single pregnant nulliparous women with a short cervix, both microionized progesterone and 
17-OHPC are recommended. The guideline also indicated that only two quality studies 
performed in few subjects support this intervention; hence, more research is required.107  
2.5 Utilization of 17-OHPC among Eligible Women from Different States 
The coverage policies and utilization of 17-OHPC vary across different states. Batra et 
al. (2017) conducted a cross-sectional study and offered a web-based survey to identify 
variations in progesterone coverage guidelines in different state Medicaid managed care 
organizations (MMCOs). Eighteen managed care organizations (MCO) plans provided 
coverage for 31 of the 39 states with MMCOs. Out of 18 MCO plans, 87.5% of respondents 
covered branded progesterone and 81.3% covered compounded progesterone. MMCO 
coverage policies varied across states: 86.7% of plans required prior authorization (PA) for 
branded 17-OHPC and 75% required PA for compounded 17-OHPC.108 
The Association of State and Territorial Health Officials (2015) published an issue brief 
on the state and territorial health agencies’ practice of promoting 17-OHPC access and use. 
Therein, Louisiana, North Carolina, Ohio, Texas, Iowa, and South California are actively 
playing a role in collaborating with Medicaid agencies, enhancing the ordering and 
administration process, improving education and partnering with key stakeholders.109  
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Louisiana Medicaid began reimbursing the administration of 17-OHPC in 2010. But 
data from the Louisiana Department of Health and Hospitals indicated that only 4.67% of 
women at risk for recurrent PTB received 17-OHPC in 2011, and this number increased slightly 
to 7.41% in 2013.110  
North Carolina has had a strong statewide 17-OHPC initiative since 2007. Injection of 
17-OHPC is covered by North Carolina Medicaid, but the prerequisite is women have to 
receive injections at the clinic. Stringer et al. (2016) conducted a retrospective cohort study 
investigating the utilization of 17-OHPC among eligible women delivering at two major North 
Carolina hospitals. Results showed only 47% of eligible women received ≥ 1 injection. For 
those who were covered, the median number of injections was 9.111 
Cross-Barnet et al. (2018) used data from Center for Medicare and Medicaid Innovation, 
which launched Strong Start programs from 2013 to 2017, and 27 awardees from over 200 sites 
in 30 states participated. They reported that 14.95% of 45,999 eligible enrolled patients 
received 17-OHPC.135 
2.6 Medication Adherence of 17-OHPC 
The medication adherence of 17-OHPC and factors related to adherence have not been 
well investigated in the real-world setting. Furthermore, since low medication adherence may 
reduce the effect of 17-OHPC in the prevention of SPTB, it is also necessary to explore the 
association between patients’ adherence and effectiveness of 17-OHPC. According to the 
guidelines, weekly injections of 17-OHPC should start between 16 and 24 weeks of gestation 
and continue until 36 weeks or delivery. Thus, when evaluating adherence, at least 10-12 
injections during the pregnancy process are needed to ensure women receiving 17-OHPC in 
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the recommended gestational window.  
Different definitions of 17-OHPC adherence were applied across different studies. 
Rittenberg et al. (2007) identified patients who did not continue 17-OHPC injections as non-
adherers. They conducted a retrospective review assessing adherence to 17-OHPC in the 
community setting. Among the included patients, 59 out of 1,979 (3%) discontinued injections 
after a single injection, and 474 out of 1,979 (24%) discontinued before 34 weeks of 
gestation.112 The authors were not able to specify reasons for patients’ discontinuation. Yee et 
al. (2016) defined adherence as no more than one missed dose to evaluate the association 
between adherence to 17-OHPC and ethnic disparities at a single institution. Of 472 women, 
83% of women were adherent to 17-OHPC. For women who were nonadherent, they were 
more likely to be non-Hispanic Black and have public insurance.113 Carter et al. (2019) 
measured the adherence by calculating the number of injections received divided by the number 
of eligible injections patients may receive from the initiation date to the delivery date. 
MarketScan data was used to explore the association between timing of 17-OHPC initiation 
and PTB risk. Instead of defining a cut-off of adherence, they reported the number and 
percentage of patients in each adherence rate range. The results showed that of 3,374 patients, 
32.3% had an adherence rate over 85% and 54.3% had an adherence rate over 60%.114 DeNoble 
et al. (2019) used the similar way to measure adherence, and they chose 70% as the minimum 
threshold for adherence, with the reason that this would the proportion if patients receive 
injections with at the maximum interval of 10 days between doses. They reported a 72.2% 
adherence rate with a sample size of 115 patients from a Duke University-affiliated hospital.115 
Three studies using Medicaid data were identified. Lucas et al. (2012) evaluated the 
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adherence with guidelines by reporting the proportion of patients initiating 17-OHPC within 
the recommended window of gestational age (16-20.9 weeks of gestation). Using data collected 
from one of Centene’s managed Medicaid programs, they found that 58.6% of 790 patients 
initiated 17-OHPC in the recommended gestational age window, and 9.2% initiated 17-OHPC 
after 26 weeks of gestation.116 Orsulak et al. (2015) defined adherence as receiving at least 10 
injections. Using Louisiana Medicaid data, they reported that 301 out of 4,091 (7.4%) eligible 
women received at least one injection of 17-OHPC in 2013, and only about half of this small 
cohort received more than 10 doses. The mean number of doses per patient was 8.3.110 Hydery 
et al. (2017) defined proportion of days covered (PDC) of 0.8 or more as the cut-off for 
adherence to investigate the outcomes and adherence of 17-OHPC in Massachusetts Medicaid. 
They found that 66.3% of the population was adherent; and medication adherence was not 
significantly associated with the rate of PTB. The study included a limitation of the possible 
overestimation of adherence.117  
In terms of factors that may be associated with adherence, maternal age was reported 
to be associated with adherence in several studies. In Haidar et al.’s study (2017), only age was 
found to be associated with adherence, with women in the 100% compliance group older than 
those in the 40-80% compliance group.118 Sutton et al. (2018) and DeNoble et al. (2019) also 
found that women with older maternal age were more likely to be adherent to 17-OHPC.115,119 
Additionally, Berhie et al. stated that non-Hispanic Black women received fewer 17-OHPC 
doses than White women, without statistically significant differences.120 Non-Hispanic Black 
women were reported to have more missed doses (p<0.001) and had later initiation of care 
(p<0.001), as detailed by Yee et al.113 Carter et al. (2019) found that a higher number of prior 
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PTBs was related to early 17-OHPC initiation; but other factors, including maternal age and 
different types of comorbidities, were not shown to be related to the timing of 17-OHPC 
initiation.114 In Hydery et al.’s study, race, number of comorbidities, and different types of 
comorbidities were not shown to be associated with adherence.117  
In summary, the adherence to 17-OHPC reported in the literature ranges between 33% 
and 83%. The reported adherence is higher from studies with a small sample size of population 
from one medical center/institution, compared to studies with a larger, more diverse sample. 
Table 2.2 summarizes studies on evaluation of 17-OHPC adherence. 
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Table 2. 2 Summary of Studies on Evaluation of 17-OHPC Adherence 
Author  Year Study Design Sample 
Size 
Adherence Definition Results 
Rittenberg et 
al.112 
2007 Retrospective view; in the 
community setting 
1979 Not adherent: not continue 17-OHPC 
injections 
 
24% discontinued before 34 
weeks of gestation (76% 
adherent) 
Lucas et al.116 2012 Retrospective cohort study; 
Centene’s managed Medicaid 
programs 
790 Adherent: initiated 17-OHPC in the 
recommended gestational age 
window (16-24 weeks of gestation) 
58.6% adherent 
 
Orsulak et al.110 
 
2015 Retrospective cohort study; 
Louisiana Medicaid 
 




Yee et al.113 
 
2016 Retrospective cohort study; at 
a single institution 
 




Hydery et al.117 
 
2017 Retrospective cohort study; 
Massachusetts Medicaid 
 
169 Adherent: proportion of days covered 






2019 Retrospective cohort study; 
EMR data from a Duke 
University-affiliated hospital 
115 Adherence rate=number of received 
injections/number of eligible 
injections; adherent: 70% 
72.2% adherent 
 
Carter et al.114 
 
2019 Retrospective cohort study; 
MarketScan database 
3374 Adherence rate= number of received 
injections/number of eligible 
injections; adherent: no cut-off 
32.3% had an adherence rate 
over 85%; 54.3% had an 




2.7 Outcome Research on Effectiveness of 17-OHPC in Preventing SPTB 
Although 17-OHPC was shown to be effective in several clinical trials and is 
recommended by guidelines for the prevention of recurrent SPTB, different demographic 
characteristics and medication adherence may affect the effectiveness of 17-OHPC. Therefore, 
outcomes research is necessary to assess the effectiveness of 17-OHPC in real-world settings.  
As for measuring the outcomes, the rate of PTB is usually used as the primary outcome, 
and duration of pregnancy and neonatal morbidity are often secondary outcomes. Most studies 
used 37 weeks of gestation as the cut-off point for PTB. Some studies have conducted 
sensitivity analyses at 35 weeks, 34 weeks, 32 weeks, and/or 28 weeks. Petrini et al. (2005) 
used 2002 national birth certificate data from New Jersey and Missouri to estimate the number 
of eligible women, rate of recurrent SPTBs, and potential reduction in the national PTB rate. 
They used a 33% reduction in PTB (reported by Meis et al.’s study75) to estimate the effect. 
The result showed the overall U.S. PTB rate would decrease by approximately 2% (p<0.001) 
with use of 17-OHPC, a modest effect on the national PTB rate.121 Rittenberg et al. (2007) 
conducted a retrospective review on data collected from an outpatient 17-OHPC administration 
program provided by Matria Healthcare from 2004 to 2006. For women who received 17-
OHPC, 37.3% experienced SPTB, 22.1% delivered at less than 35 weeks, and 9.0% delivered 
at less than 32 weeks.112 Hydery et al. (2017) conducted a retrospective cohort study using 
Massachusetts Medicaid data from 2011 to 2015, and the primary outcome was term delivery 
at 37 weeks. They found that 62.1% of patients receiving progesterone had a term delivery, 
which is consistent with progesterone effectiveness obtained from clinical trials.117  
However, the three studies above only described the percentage of patients having PTB 
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among patients receiving 17-OHPC, instead of testing the difference in PTB rate between 
patients with and without 17-OHPC. Turitz et al. (2016) performed a cross-sectional study from 
2009 to 2013, and no difference in rate of SPTB was observed between women who did and 
did not use 17-OHPC (37.2% vs. 34.0%, p=0.7). Moreover, the utilization of 17-OHPC was 
not associated with patients’ race, obesity, or insurance status.122 Nelson et al. (2017) conducted 
a prospective cohort study from 2012 to 2016 in a single medical center. By using recurrence 
of birth ≤ 35 weeks as the primary outcome, the overall rate of recurrent PTB was 25.0% 
compared to the expected rate 16.8% (p=1.0).98 DeNoble et al. (2019) compared the PTB rate 
by receipt of 17-OHPC, and no significant difference in PTB rate was observed between 
patients with or without 17-OHPC (25.7% vs. 28.6%, p=0.52).115 
Using duration of pregnancy as the outcome, Bastek et al. (2012) conducted a cross-
sectional study of PTB rate and gestational age distribution at delivery from 2004 to 2009 at 
an urban academic medical center at Pennsylvania. Results showed administration of 17-OHPC 
resulted in a 10-day shift of gestational ages (31.6 to 33.1 weeks) toward delivery at late 
preterm (OR = 2.3, 95% CI = 1.49–3.54).123 A secondary analysis of women enrolled in Meis 
et al.’s study75 was conducted by Spong et al. (2005). This study also concluded that 17-OHPC 
can prolong pregnancy overall (38.0 weeks vs. 36.7 weeks, p=0.004), especially for women 
with a prior SPTB before 34 weeks of gestation.124 However, Nelson et al. (2017) found no 
significant difference in weeks of gestation (p=0.63).98 Table 2.3 summarized studies on 
effectiveness of 17-OHPC in the real-world settings. 
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Table 2. 3 Summary of Real-World Evidence on Effectiveness of 17-OHPC 
Author Year Data Source Research Type Delivery Outcome Results 
Petrini et al.121 2005 National birth certificate 
data from New Jersey 




PTB rate For the overall U.S., use of 17-OHPC has a 
modest effect on the national preterm birth 





2007 Matria Healthcare  Retrospective 
cohort study 
 
PTB rate For women who received 17-OHPC, 37.3% 
experienced SPTB; 22.1% delivered at less 
than 35 weeks; and 9.0% delivered at less 
than 32 weeks.  
Bastek et al.123 2012 An academic medical 





Administration of 17-OHPC caused a 10-
days shift of gestational ages toward delivery 
at late preterm (OR = 2.3, 95% CI = 1.49–
3.54).  




PTB rate No difference in rate of PTB was observed 
between women who used and did not use 
17-OHPC (37.2% vs. 34.0%, p=0.7).  
 
Hydery et al.117 2017 Massachusetts Medicaid Retrospective 
cohort study 
PTB rate 62.1% of patients receiving progesterone had 
a term delivery.  
 
 
Nelson et al.98 2017 Parkland hospital Prospective 





17-OHPC was ineffective for prevention of 
recurrent PTB in terms of both PTB rate 
(p=1.0) and duration of gestation (p=0.63). 
 









PTB rate No significant difference in PTB rate was 
observed between patients with or without 




The association between medication adherence and the outcome of 17-OHPC has been 
also investigated. Low adherence rates are thought to reduce the effectiveness of 17-OHPC in 
several studies. Rebarber et al. (2007) conducted a retrospective cohort study to identify the 
effect of early cessation of 17-OHPC. They identified eligible women who initiated 17-OHPC 
at 16-20 weeks gestational age. One group terminated the use of 17-OHPC before 32 weeks, 
and the other group received injections until delivery or 37 weeks. They concluded that early 
cessation of 17-OHPC injection was associated with an increased risk of recurrent SPTB, using 
endpoints of 37 weeks (48.1% vs. 33.3%, p=0.01), 35 weeks, or 32 weeks of gestation.125 Ning 
et al.’s study (2017) suggested women with early-start 17-OHPC (14-16 weeks) have lower 
rates of recurrent PTB <37 weeks, compared to those with late-start 17-OHPC (17-27 weeks) 
(41.3% vs. 57.7%, P = 0.065). Women with early 17-OHPC initiation also had lower rates of 
major neonatal morbidity (1.5% vs. 14.3%, p=0.005).126 Carter et al. (2019) reported that less 
adherent patients (receiving <25% of recommended doses) were more likely to have PTB than 
those receiving >85% of recommended doses (aRR=0.15, 95%CI=1.2-1.7, p=0.01).114 
However, some studies reported no association between adherence and outcome of 17-OHPC. 
Lucas et al. (2012) found no significant difference in SPTB rate for women initiating 17-OHPC 
at an early gestational age (16-20.9 weeks) versus those initiating after 20.9 weeks (34.3% vs. 
36.1%, p=0.61).116 Haidar et al. (2017) conducted a secondary analysis based on a prospective 
study which categorized women into two groups—one with a 100% compliance rate (full 
compliance, n=370) and another with a 40%-80% compliance rate (partial compliance, n=35). 
By comparing the two groups, they concluded that injections of 17-OHPC significantly 
decreased recurrent PTB in both groups, but no significant differences in neonatal outcomes 
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were found (27.0% vs. 31.3%, p=0.52).118  
In summary, currently, no consensus has been reached on the effectiveness of 17-OHPC 
in terms of either reducing recurrent SPTB rate, prolonging women’s duration of pregnancy, or 
improving neonatal birth outcomes. Hence, it is still necessary to conduct more research using 
large databases to investigate the real-world effectiveness of 17-OHPC. 
2.8 Adverse Effects of 17-OHPC 
In addition to effectiveness of 17-OHPC, both clinical trials and outcomes studies 
reported adverse effects of 17-OHPC. Since adverse effects may also be one of the reasons for 
underutilization and inadequate medication adherence of 17-OHPC, it is necessary to study the 
relationship between use of 17-OHPC and incidence of adverse effects. Most side effects of 
17-OHPC are injection-site related reactions. In Meis et al.’s trial (2003), 50% of patients 
reported at least one adverse side effect, including injection site soreness (34.2%), swelling 
(14.1%), itching (11.3%), and bruising (6.7%). Women in the 17-OHPC group were 
significantly more likely to have swelling and a lump at the injection site compared to the 
placebo group.75 In an RCT using 17-OHPC (2009), 35% of participants reported injection site 
pain, 17% experienced injection site swelling, 12% had urticaria; and the incidences of pruritus, 
nausea and vomiting, and injection site nodule were 8%, 6%, and 4%, respectively.127  
In addition to injection-site related reactions, some maternal complications may be also 
associated with use of 17-OHPC. One potential risk of 17-OHPC is that it may be related to a 
higher risk of gestational diabetes mellitus (GDM). Theoretically, progestogens can alter the 
physiology of glucose transport into cells and may also impact the release of insulin.128 
Rebarber et al. (2007) found that for patients with similar maternal BMI and age, the incidence 
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of GDM was higher for women receiving 17-OHPC (OR=2.9, 95% CI=2.1-4.1).125 This seems 
also applicable to obese women. Egerman et al. (2014) retrospectively identified obese 
singleton pregnant women with BMI  30 kg/m2, excluding women with history of diabetes or 
GDM during previous pregnancies. The analysis results showed that for obese women greater 
than 35 years old, early initiation of 17-OHPC may increase the risk of GDM (13.8% vs. 9.6%, 
p=0.048).129 A prospective cohort study conducted by Nelson et al. (2017) also reported that 
the use of 17-OHPC was associated with an increase of gestational diabetes (13.4% vs. 8%, 
p=0.001).98 The association between GDM and the use of 17-OHPC has been disputed, 
however, Gyamfi et al. (2009) conducted a secondary analysis of a clinical trial, which included 
1094 women with 411 singleton and 653 twin pregnancies. Either in singleton or twin 
pregnancies, no association was found between higher rates of GDM and administration of 17-
OHPC.128 A similar conclusion was also made by Rouholamin et al (2015).130 
Gestational hypertension (GHT) and preeclampsia are also listed on the Makena billing 
guide listed as possible maternal complications of Makena based on the results from Meis’s 
clinical trial (8.8% in the treatment group versus 4.6% in the control group).75,99 However, the 
effect of 17-OHPC in decreasing blood pressure has been noted in recent literature. Sammour 
et al. (2005) indicated that the prevention of hypertensive disorders seemed possible by using 
progesterone.131 Ngai et al. (2014) evaluated the association between preeclampsia and 17-
OHPC, with concerns that 17-OHPC may increase the risk of preeclampsia. However, no 
association was found between incidence of preeclampsia and 17-OHPC, with preeclampsia 
incidence of 2.5% in the treatment group and 5.6% in the control group (p=0.27).132 The study 
conducted by Amaral et al. (2015) illustrated that 17-OHPC’s effect of decreasing blood 
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pressure made it possible to be considered as a viable addition to preeclampsia treatment.133 
Cottrell et al. (2019) found that 17-OHPC could improve hypertension in response to elevated 
soluble fms-like tyrosine kinase-1.134  
Thus, more studies need to be conducted to confirm the relationships between incidence 
of GDM, GHT, or preeclampsia and 17-OHPC utilization. 
2.9 Summary of Literature Review 
In summary, 1) 17-OHPC is recommended by guidelines to prevent recurrent SPTB; 
however, overall, it is underutilized; 2) there is no consensus on the effectiveness of 17-OHPC 
for preventing SPTB in real-world settings; 3) few studies have investigated adherence rates of 
17-OHPC and no consistent definition was applied to evaluate 17-OHPC adherence across 
different studies; 4) the consequences of low medication adherence have not been adequately 
addressed; 5) there is no consensus regarding the association of the incidence of GDM, GHT, 
or preeclampsia and the use of 17-OHPC.  
2.10 Study Aim 
This study aims to address gaps in the literature by: 1) evaluating the utilization of 17-
OHPC among eligible women using Decision Resources Group (DRG) databases; 2) 
comparing characteristics between women who did and did not receive 17-OHPC during their 
pregnancy; 3) evaluating medication adherence to 17-OHPC; 4) identifying characteristics of 
those who were adherent versus non-adherent; 5) investigating associations between utilization 
and adherence status of 17-OHPC and the incidence of PTB in the real-world setting; and 6) 
determining if 17-OHPC utilization is associated with the incidence of GDM, GHT, or 
preeclampsia.   
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Chapter 3 Methods 
3.1 Institutional Review Board Approval 
This study was approved by The University of Texas at Austin Institutional Review 
Board. All data were in a de-identified form. 
3.2 Objectives and Hypotheses 
Generally, the aims of this study were to evaluate the utilization, adherence, and 
effectiveness of 17-OHPC among pregnant women at risk of preterm birth in a real-world 
setting. The specific objectives and hypotheses are listed below: 
1) To describe characteristics of pregnant women with high PTB risk and utilization of 
17-OHPC among eligible women; 
2) To compare differences between high PTB risk pregnant women with and without 
17-OHPC by their age group, insurance type, geographic region, pre-index diabetes, 
pre-index hypertension, pre-index Charlson comorbidity index (CCI) score, and pre-
index diagnoses of alcohol, tobacco, or drug abuse; 
2a) H0: There is no significant difference in age between high PTB risk pregnant 
women with and without 17-OHPC.  
      H1: There is significant difference in age between high PTB risk pregnant 
women with and without 17-OHPC.  
      2b) H0: There is no significant difference in insurance type between high PTB risk 
pregnant women with and without 17-OHPC. 
            H1: There is significant difference in insurance type between high PTB risk 
pregnant women with and without 17-OHPC. 
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      2c) H0: There is no significant difference in geographic region between high PTB 
risk pregnant women with and without 17-OHPC. 
             H1: There is significant difference in geographic region between high PTB risk 
pregnant women with and without 17-OHPC. 
      2d) H0: The initiation of 17-OHPC is not significantly related to whether pregnant 
women with high PTB risk had pre-index diabetes or not. 
             H1: The initiation of 17-OHPC is significantly related to whether pregnant 
women with high PTB risk had pre-index diabetes or not. 
      2e) H0: The initiation of 17-OHPC is not significantly related to whether pregnant 
women with high PTB risk had pre-index hypertension or not. 
            H1: The initiation of 17-OHPC is significantly related to whether pregnant 
women with high PTB risk had pre-index hypertension or not. 
      2f) H0: There is no significant difference in proportion of different pre-index CCI 
score between high PTB risk pregnant women with and without 17-OHPC. 
            H1: There is significant difference in proportion of different pre-index CCI score 
between high PTB risk pregnant women with and without 17-OHPC. 
      2g) H0: The initiation of 17-OHPC is not significantly related to whether pregnant 
women with high PTB risk had pre-index diagnoses of alcohol, tobacco, or 
drug abuse or not. 
            H1: The initiation of 17-OHPC is significantly related to whether pregnant 
women with high PTB risk had pre-index diagnoses of alcohol, tobacco, or 
drug abuse or not. 
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3) To assess medication adherence of high PTB risk pregnant women receiving 17-
OHPC; 
4) To investigate the association between medication adherence and patients’ age, 
insurance type, post-index diabetes, post-index hypertension, post-index CCI score, 
and post-index alcohol, tobacco, or drug abuse; 
 4a) H0: There is no significant difference in age between high PTB risk pregnant 
women with and without adequate medication adherence.  
       H1: There is significant difference in age between high PTB risk pregnant 
women with and without adequate medication adherence.  
 4b) H0: There is no significant difference in insurance type between high PTB risk 
pregnant women with and without adequate medication adherence.  
       H1: There is significant difference in insurance type between high PTB risk 
pregnant women with and without adequate medication adherence.  
4c) H0: There is no significant difference in proportion of post-index diabetes 
diagnoses between high PTB risk pregnant women with and without 
adequate medication adherence. 
      H1: There is significant difference in proportion of post-index diabetes 
diagnoses between high PTB risk pregnant women with and without 
adequate medication adherence. 
4d) H0: There is no significant difference in proportion of post-index hypertension 
diagnoses between high PTB risk pregnant women with and without 
adequate medication adherence. 
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       H1: There is significant difference in proportion of post-index hypertension 
diagnoses between high PTB risk pregnant women with and without 
adequate medication adherence. 
4e) H0: There is no significant difference in proportion of different post-index CCI 
score between high PTB risk pregnant women with and without 17-OHPC.  
       H1: There is significant difference in proportion of different post-index CCI 
score between high PTB risk pregnant women with and without 17-OHPC.  
4f) H0: There is no significant difference in proportion of post-index diagnoses of 
alcohol, tobacco, or drug abuse between high PTB risk pregnant women 
with and without 17-OHPC. 
       H1: There is no significant difference in proportion of post-index diagnoses of 
alcohol, tobacco, or drug abuse between high PTB risk pregnant women 
with and without 17-OHPC. 
5) To evaluate the association between the incidence of PTB and patients’ age, 
insurance type, geographic region, post-index CCI score, and alcohol, tobacco, or 
drug abuse;  
5a) H0: There is no significant difference in age between high PTB risk pregnant 
women with and without PTB. 
      H1: There is significant difference in age between high PTB risk pregnant 
women with and without PTB. 
5b) H0: There is no significant difference in insurance type between high PTB risk 
pregnant women with and without PTB. 
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      H1: There is significant difference in insurance type between high PTB risk 
pregnant women with and without PTB. 
5c) H0: There is no significant difference in geographic region between high PTB 
risk pregnant women with and without PTB. 
       H1: There is significant difference in geographic region between high PTB risk 
pregnant women with and without PTB. 
5d) H0: There is no significant difference in proportion of post-index diabetes 
diagnoses between high PTB risk pregnant women with and without PTB. 
      H1: There is significant difference in proportion of post-index diabetes 
diagnoses between high PTB risk pregnant women with and without PTB. 
5e) H0: There is no significant difference in proportion of post-index hypertension 
diagnoses between high PTB risk pregnant women with and without PTB. 
       H1: There is significant difference in proportion of post-index hypertension 
diagnoses between high PTB risk pregnant women with and without PTB. 
5f) H0: There is no significant difference in proportion of different post-index CCI 
score between high PTB risk pregnant women with and without PTB. 
       H1: There is significant difference in proportion of different post-index CCI 
score between high PTB risk pregnant women with and without PTB. 
5g) H0: There is no significant difference in proportion of post-index alcohol, 
tobacco, or drug abuse diagnoses between high PTB risk pregnant women 
with and without PTB. 
      H1: There is significant difference in proportion of post-index alcohol, tobacco, 
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or drug abuse diagnoses between high PTB risk pregnant women with and 
without PTB. 
6) To investigate the association between incidence of PTB and utilization and 
adherence status of 17-OHPC. 
6a) H0: There is no significant difference in PTB rate between high PTB risk 
pregnant women with and without 17-OHPC. 
      H1: There is significant difference in PTB rate between high PTB risk pregnant 
women with and without 17-OHPC. 
6b) H0: There is no significant difference in PTB rate between high PTB risk 
pregnant women with and without adequate medication adherence. 
      H1: There is significant difference in PTB rate between high PTB risk pregnant 
women with and without adequate medication adherence. 
6c) H0: There is no association between PTB rate and utilization and adherence 
status of high PTB risk pregnant women (non-17-OHPC users, adherers, 
non-adherers). 
       H1: There is significant association between PTB rate and utilization and 
adherence status of high PTB risk pregnant women (non-17-OHPC users, 
adherers, non-adherers). 
6d) H0: There is no association between PTB rate and utilization and adherence 
status of high PTB risk pregnant women (non-17-OHPC users, adherers, 
non-adherers), controlling for other covariates (patients’ age, insurance 
type, geographic region, post-index CCI score, and post-index diagnoses 
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of alcohol, tobacco, or drug abuse). 
       H1: There is significant association between PTB rate and utilization and 
adherence status of high PTB risk pregnant women (non-17-OHPC users, 
adherers, non-adherers), controlling for other covariates (patients’ age, 
insurance type, geographic region, post-index CCI score, and post-index 
diagnoses of alcohol, tobacco, or drug abuse). 
7) To explore if incidence of diabetes (including GDM) or hypertension (including GHT 
and preeclampsia) is associated with utilization and adherence status of 17-OHPC. 
7a) H0: The use of 17-OHPC is not significantly associated with the incidence of 
diabetes. 
       H1: The use of 17-OHPC is significantly associated with the incidence of 
diabetes. 
7b) H0: The adherence of 17-OHPC is not significantly associated with the 
incidence of diabetes. 
       H1: The adherence of 17-OHPC is not significantly associated with the 
incidence of diabetes. 
7c) H0: The incidence of diabetes is not significantly associated with utilization and 
adherence status of 17-OHPC (non-17-OHPC users, adherers, non-
adherers). 
       H1: The incidence of diabetes is significantly associated with utilization and 




7d) H0: The use of 17-OHPC is not significantly associated with the incidence of 
hypertension. 
       H1: The use of 17-OHPC is significantly associated with the incidence of 
hypertension. 
7e) H0: The adherence of 17-OHPC is not significantly associated with the 
incidence of hypertension. 
       H1: The adherence of 17-OHPC is significantly associated with the incidence 
of hypertension. 
7f) H0: The incidence of hypertension is not significantly associated with utilization 
and adherence status of 17-OHPC (non-17-OHPC users, adherers, non-
adherers). 
     H1: The incidence of hypertension is significantly associated with utilization and 
adherence status of 17-OHPC (non-17-OHPC users, adherers, non-
adherers). 
3.3 Study Design 
This was a retrospective cohort study using a secondary database, the Decision 
Resources Group (DRG) claims database. The DRG database contains information from over 
300 million patients and over 1.8 million health care providers in the U.S. Patients’ 
demographic information (age, race, gender, geographic region), medical claims, and 
pharmacy claims were provided in the database. In terms of patient coverage by state, the 
highest medical claims coverage was in the Eastern U.S., with more than 60% coverage in 
Maryland, New Jersey, New York, Ohio, Pennsylvania, Maine, West Virginia, and Washington 
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DC. The pharmacy claims were concentrated in the center of the country, with more than a 46% 
capture in Kentucky, West Virginia, Ohio, and Michigan. In terms of health care providers’ 
information, variables including national provider identifier, affiliation hierarchy, treatment 
settings (in-patient or out-patient), and line item charge details were included in the DRG 
database. 
The data were drawn from the DRG claims database from January 1, 2012 to December 
31, 2017. Women with a high risk of PTB, operationalized as having a history of PTB (see 
section 3.4.1), were included. The first diagnosis date of high-risk pregnancy for each patient 
was defined as the index date. The pre-index period was 6 months before the index date, and 
the pre-index period was necessary to guarantee the feasibility of evaluating the relationship 
between pre-index comorbidities and 17-OHPC utilization status. The patients were followed 
up until their delivery, which may happen during the 9 months after the index date. The study 
timeline is demonstrated by Figure 3.1. Information extracted from the DRG databases is listed 









Figure 3. 1 Study Timeline 
  
1/1/2012 12/31/2017 
Pre-index period: 6 months 
9 months post 
the index date 




3 months post 
the index date 
Index date:  





Table 3. 1 Decision Resources Group Database Variables Information 
Variable name Description 
PATIENT_SUFFIX Unique Patient Identifier 
PATIENT_GENDER Patient gender (M=male, F=female, U=unknown) 
PATIENT_DOB Patient's birth year 
RACE Racial profile of the Patient 
ETHNICITY Ethnic profile of the Patient 
PRIMARY_DIAGNOSIS 
The standard diagnosis codes associated with the claim 
based on the relevance to the encounter (primary diagnosis 
- reason for visit) 
DIAGNOSIS_CODE_2 
The standard diagnosis codes associated with the claim 
based on the relevance to the encounter, level 2 
DIAGNOSIS_CODE_3 
The standard diagnosis codes associated with the claim 
based on the relevance to the encounter, level 3 
DIAGNOSIS_CODE_4 
The standard diagnosis codes associated with the claim 
based on the relevance to the encounter, level 4 
DIAGNOSIS_CODE_5 
The standard diagnosis codes associated with the claim 
based on the relevance to the encounter, level 5 
DIAGNOSIS_CODE_6 
The standard diagnosis codes associated with the claim 
based on the relevance to the encounter, level 6 
DIAGNOSIS_CODE_7 
The standard diagnosis codes associated with the claim 
based on the relevance to the encounter, level 7 
DIAGNOSIS_CODE_8 
The standard diagnosis codes associated with the claim 
based on the relevance to the encounter, level 8 
PROCEDURE CPT/ HCPCS code 
PROCEDURE_TYPE ICD 9.10 procedure= ICD or HCPCS/CPT = CPT 
NDC National Drug Code 
PLACE_SERVICE HIPAA standard place of service code set 
SERVICE_FROM First date of service 
SERVICE_TO Last date of service 
STATEMENT_FROM First date of service for an inpatient stay 
STATEMENT_TO Last date of service for an inpatient stay 
FACILITY_NPI Facility National Provider Identifier  
FACILITY_ADR_STATE Facility State 
FACILITY_ADR_CITY Facility City 
TYPE_COVERAGE Payer type ID (commercial, Medicare, Medicaid etc.)  
MIN_DIAG_DATE First diagnosis date of preterm labor 
DELIVERY_DATE 
Delivery date of the Patient for that particular episode of 
Pregnancy 
PROG_TREATED 
Flag indicating whether the patient was treated with 
Progesterone therapy or not 
3.4 Study Population 
3.4.1 Population Inclusion Criteria 
Patients were included if they met the following criteria: (a) female; (b) age>16 years 
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and <50 years; (c) diagnoses of “Pregnancy with history of pre-term labor” or “Personal history 
of pre-term labor” based on International Classification of Diseases, Ninth Revision, Clinical 
Modification (ICD-9-CM), V23.41 and V13.21, and International Classification of Diseases, 
Tenth Revision, Clinical Modification (ICD-10-CM), O09.21 and Z87.51; (d) were 
continuously enrolled for at least 6 months before the index date; (e) and had a delivery date 
recorded. Only women aged >16 years and <50 years were included, because women who are 
younger than 16 years and who are older than 50 years face higher risks of PTB, and these 
groups only accounted for a small proportion of total sample.  
3.4.2 Population Exclusion Criteria 
Women were excluded if they: (a) had multiple gestations (ICD-9-CM: 651.xx, 
652.xx, V31.xx, V32.xx, V33.xx, V34.xx, V35.xx, V36.xx, V37.xx; ICD-10-CM: O30.xx, 
O32.xx, Z37.2x, Z37.3x, Z37.4x, Z37.5x, Z37.6x, Z37.7x, Z38.3x, Z38.4x, Z38.5x, Z38.6x, 
Z38.7x, Z38.8x); (b) had cervical shortening (ICD-9-CM: 649.7x; ICD-10-CM: O26.87x); (c) 
had cervical cerclage (Current Procedural Terminology (CPT) code, 59320); and (d) the 
delivery took place within 3 months- or after 9 months- post the index date. If a woman’s 
recorded delivery date is more than 9 months after the index date, it is probable that the 
delivery is the outcome of another pregnancy rather than the one that was used to identify the 
index date. Thus, they were excluded in this study. The women with a delivery date within 3 
months after the index date were also excluded, because they may have seen the physician at 
a later gestational age, and even if 17-OHPC was initiated on the index date, they were less 
likely to receive at least 10 injections (prerequisite of adequate adherence) compared to other 
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patients. Since this may affect the evaluation of adherence and effectiveness of 17-OHPC, 
these women were also excluded. 
3.5 Study Variables 
3.5.1 Independent Variables 
Independent variables included patients’ age group, insurance type, geographic region, 
comorbidity (diabetes and hypertension), CCI, abuse of alcohol, tobacco or drugs, utilization 
and adherence status of 17-OHPC. The independent variables differ according to different 
study objectives. 
For objective 1, the baseline demographic and clinical characteristics of included 
patients were described, which included age group, insurance type, geographic region, pre-
index diabetes, pre-index hypertension, pre-index CCI, pre-index abuse of alcohol, tobacco, or 
drugs. The age groups consisted of ages: 16 and <20 years; 20 and <25 years; 25 and <30 
years; 30 and <35 years; 35 and <40 years; and 40 and 50 years. Insurance type was 
categorized as Medicaid, commercial insurance plan, and others. Patients who were dually 
eligible for Medicaid and any other insurance were categorized as Medicaid patients. As for 
the comorbidities, since the billing guide of Makena indicated that physicians should be more 
vigilant when prescribing Makena for patients with a diagnosis of  diabetes or hypertension,99 
if patients had diabetes or hypertension diagnoses recorded before the first high-risk pregnancy 
diagnosis date (i.e. index date), their chance of receiving 17-OHPC may be affected. Thus, the 
proportion of women with pre-index diabetes or hypertension was included. The pre-index CCI 
score and the proportion of the sample with a diagnosis of alcohol, tobacco, or drug abuse were 
also described in the objective 1. In addition, the post-index clinical characteristics of the 
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sample were also described, because they were compared in objective 4. 
For objective 2, age group, insurance type, geographic region, pre-index diabetes, pre-
index hypertension, pre-index CCI, and pre-index abuse of alcohol, tobacco, or drugs were 
compared among the 17-OHPC and non-17-OHPC cohorts.  
For objectives 3 and 4, the independent variables included the baseline demographic 
characteristics (age group, insurance type) and the post-index clinical characteristics (diabetes, 
hypertension, CCI, and abuse of alcohol, tobacco, or drug). The post-index diabetes diagnoses 
included GDM; the post-index hypertension diagnoses included GHT and preeclampsia. These 
characteristics were compared among non-adherers and adherers. The post-index clinical 
characteristics were compared because some women may have gestational diabetes, gestational 
hypertension, or other maternal complications after the index date, and the adherence of 17-
OHPC may be affected by both pre-index comorbidities and the conditions that were diagnosed 
during the post-index period (including comorbidities and maternal complications).  
The independent variables for objective 5 were age group, insurance type, geographic 
region, post-index diabetes, post-index hypertension, post-index CCI, and post-index abuse of 
alcohol, tobacco, or drugs. The post-index clinical characteristics were applied here because 
the post-index comorbidities and maternal complications may better characterize a women’s 
risk of having PTB than the pre-index clinical characteristics. 
In objectives 6 and 7, the independent variable was the utilization and adherence status 
of 17-OHPC, specifically whether women were adherers, non-adherers, or non-17-OHPC users. 
3.5.2 Dependent Variables 
Dependent variables include utilization of 17-OHPC, medication adherence, incidence 
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of PTB, incidence of diabetes, and incidence of hypertension.  
Whether patients used 17-OHPC or not is the dependent variables for objective 2. Being 
adherent or not adherent to 17-OHPC is the dependent variable for objectives 3 and 4. In terms 
of medication adherence measurement, since the guidelines suggested injections of 17-OHPC 
should start between 16-24 weeks and continue until 36 weeks or delivery, 10 weeks of 
injections was used as the preliminary cut-off for adequate adherence. In order to further 
calculate adherence, the number of days between the delivery date and the first claim date of 
17-OHPC injection was calculated, and then was divided by 7 (ceil this number) to get the 
maximum number of weeks that patients were able to receive injections. For those with greater 
than or equal to 10 weeks of injection, if the received number of injections divided by the 
maximum number of weeks that patients should get injections is greater than 0.7, the patient 
was considered to be adherent to 17-OHPC; otherwise, the patient was considered nonadherent 
(Table 3.2). For example, if a woman initiated 17-OHPC at the 20th week of gestation and 
delivered at the 35th week of gestation, her adherence would be 100% if she received 16 
injections. However, if she received 10 injections, then her adherence rate would be 62.5% (10 
received injections out of 16 possible injections), and, thus, she would be treated as a non-
adherer. If another woman initiated 17-OHPC at the 28th week of gestation and delivered at the 
36th week of gestation, she would be treated as a non-adherer even if she received 9 injections 
out of 9 possible injections, because she did not initiate the drug in the recommended 
gestational window. In the sensitivity analysis, 10 weeks of injection was used as the cut-off 
for adequate adherence. 
The dependent variable for objectives 5 and 6 was the incidence of PTB. The incidence 
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of diabetes (including GDM) and incidence of hypertension (including GHT or preeclampsia) 
were the dependent variables for objective 7.  




0 # of 17-OHPC < 10 
0 # of 17-OHPC ≥ 10; and 
# of 17 − OHPC injections
(delivery date −  first Rx date)/7
< 0.7 
1 # of 17-OHPC ≥ 10; and 
# of 17 − OHPC injections
(delivery date −  first Rx date)/7
≥ 0.7 
* Ceil the denominator: (delivery date-first Rx date)/7 
3.5.3 Study Covariates 
The available factors that could confound the relationship between the incidence of 
PTB and the utilization and adherence status of 17-OHPC were examined and controlled for in 
the study. For objective 6, age, insurance type, geographic region, post-index diabetes, post-
index hypertension, post-index CCI, and post-index abuse of alcohol, tobacco, or drugs were 
used as covariates in the regression model. 





Table 3. 3 Summary of Included Variables and Their Operational Definitions 
Variables Operational Definition 
Age group  16 and < 20 years;  20 and < 25 years; 
 25 and < 30 years;  30 and < 35 years;  
 35 and < 40 years;  40 and  50 years 
Insurance type Medicaid 
Commercial insurance 
Others 





Pre-index diabetes 0 = no diabetes 
1 = with diabetes 
Pre-index hypertension 0= no hypertension 
1= with hypertension 




Pre-index abuse of alcohol, tobacco 
or drug 
0= no abuse of alcohol, tobacco or drug 
1= with abuse of alcohol, tobacco or drug 
Post-index diabetes (including 
GDMb) 
0 = no diabetes 
1 = with diabetes 
Post-index hypertension (including 
GHTc and preeclampsia) 
0= no hypertension 
1= with hypertension 




Post-index abuse of alcohol, tobacco 
or drug 
0= no abuse of alcohol, tobacco or drug 
1= with abuse of alcohol, tobacco or drug 
Use of 17-OHPC 0 = non-17-OHPC user 
1 = 17-OHPC user 
Medication adherence 0 = Not adherent  
1 = Adherent  
Utilization and adherence status of 
17-OHPC 
0 = non-17-OHPC user 
1 = non-adherer 
2 = adherer 
Incidence of PTBd 0 = no PTB 
1 = with PTB  
Incidence of diabetes (including 
GDMb) 
0 = no diabetes 
1 = with diabetes 
Incidence of hypertension (including 
GHTc and preeclampsia) 
0= no hypertension 
1= with hypertension 
a CCI= Charlson Comorbidity Index  
b GDM=Gestational diabetes 
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c GHT=Gestational hypertension 
d PTB=Preterm birth 
3.6 Statistical Analyses 
All statistical analyses were performed using SAS software v.9.4. An alpha level of 0.05 
was used for all statistical analyses. 
Descriptive statistics (i.e., mean, standard deviation, frequency) were used to 
summarize the baseline characteristics and post-index clinical characteristics of the sample in 
objective 1.  
The proportion of the study population who were 17-OHPC or non-17-OHPC cohorts, 
and the proportion of 17-OHPC utilization by year were investigated in objective 2. Chi-square 
tests were conducted to evaluate the association between patients’ use of 17-OHPC (yes/no) 
and their age, insurance type, geographic region, proportion of pre-index diabetes, proportion 
of pre-index hypertension, pre-index CCI, and proportion of pre-index alcohol, tobacco, or 
drug abuse. 
The proportion of study cohorts who were adherent versus not adherent was described 
for objective 3. Chi-square tests were conducted for objective 4 to evaluate the association 
between patients’ adherence of 17-OHPC (yes/no) and their age, insurance type, proportion of 
post-index diabetes, proportion of post-index hypertension, post-index CCI, and proportion of 
post-index alcohol, tobacco, or drug abuse. 
Chi-square tests were also conducted for objective 5 to examine the association between 
the incidence of PTB (yes/no) and patients’ age, insurance type, geographic region, post-index 
diabetes, post-index hypertension, post-index CCI, and proportion of post-index alcohol, 
tobacco, or drug abuse. 
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In objective 6, bivariate analyses (Chi-square tests) were conducted to evaluate the 
association between the incidence of PTB (yes/no) and use of 17-OHPC (yes/no), the 
association between the incidence of PTB (yes/no) and adherence of 17-OHPC (yes/no), as 
well as the association between the incidence of PTB (yes/no) and utilization and adherence 
status of 17-OHPC (non-users/non-adherers/adherers). The association between the incidence 
of PTB and utilization and adherence status of 17-OHPC (non-users/non-adherers/adherers) 
was also evaluated after controlling the covariates by conducting logistic regression analysis. 
In objective 7, the aim was to investigate if use of 17-OHPC was associated with the 
incidence of diabetes or hypertension, and, thus, the proportion of patients with newly-
diagnosed diabetes or hypertension after their initiation of 17-OHPC injection would be 
calculated.  However, for the non-users cohort, it was impossible to use the 17-OHPC initiation 
date as the cut-off to calculate the proportion of newly diagnosed diabetes or hypertension 
patients. By checking the difference in days between the index day and the 17-OHPC initiation 
day, it was found that more than 95% of women initiated 17-OHPC on the index day. Therefore, 
the index date (first diagnoses for history of PTB) was used as the proxy for 17-OHPC initiation 
date. Chi-square tests were applied as well to investigate if 17-OHPC utilization and adherence 
was associated with the incidence of diabetes or hypertension after the index date. 
Table 3.4 summarizes study objectives, their corresponding independent variables, 





Table 3. 4 Summary of Objectives, Study Variables, and Statistical Tests 
 
 
Objectives Dependent Variables Independent Variables Covariates Statistical Analysis 
1)  To describe patients’ 
baseline characteristics  
N/A N/A N/A Descriptive statistics 
(i.e. mean, standard 
deviation, 
frequency) 
2) To describe 17-OHPC 
utilization and compare 
baseline characteristics by 
utilization status of 17-
OHPC 
Use of 17-OHPC 
(categorical) 
Age group, insurance type, geographic 
region, pre-index diabetes, pre-index 
hypertension, pre-index CCI, pre-index 
abuse of alcohol, tobacco, or drug 
(categorical);   
N/A Chi-square test 
 
3)  To assess medication 
adherence of women 
receiving 17-OHPC 
Adherence to 17-OHPC  
(categorical) 
N/A N/A Descriptive statistics 
(i.e. mean, standard 
deviation, 
frequency) 
4)   To compare patients’ 
characteristics by 
adherence status of 17-
OHPC 
Adherence to 17-OHPC  
(categorical) 
Age group, insurance type, post-index 
diabetes, post-index hypertension, post-
index CCI, and post-index abuse of 
alcohol, tobacco, or drug (categorical) 
N/A Chi-square test 
 
5)  To compare patients’ 
characteristics by delivery 
outcome 
Incidence of PTB 
(categorical) 
Age group, insurance type, geographic 
region, post-index diabetes, post-index 
hypertension, post-index CCI, and post-
index abuse of alcohol, tobacco, or drug 
(categorical) 








Objectives Dependent Variables Independent Variables Covariates Statistical Analysis 
6)  To compare delivery 
outcome by utilization and 
adherence status of 17-
OHPC 
Incidence of PTB 
(categorical) 
Utilization and adherence status of 17-
OHPC (categorical) 





index CCI, and post-
index abuse of 





7) To determine if 
utilization and adherence 
status 17-OHPC is related 
to incidence of diabetes or 
hypertension 




GHT and preeclampsia) 
(categorical) 
Utilization and adherence status of 17-
OHPC (categorical) 
N/A Chi-square test 
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Chapter 4 Results  
This chapter provides a detailed description of the study results, including the sample 
attrition process and other results, which are presented in the corresponding order of study 
objectives outlined in Chapter 3. 
4.1 Sample Selection 
Initially, data for 216,609 patients were included from the Decision Resource Group 
(DRG) database, with at least one diagnosis code of “supervision of high-risk pregnancy, with 
history of pre-term labor.” A small proportion of patients may share insurance with their 
husbands or other family members, which potentially resulted in some patients’ gender shown 
in the claims databases as male. After excluding patients with “male” gender in the database, 
216,160 female patients were left. When including women between 16 and 50 years, 215,217 
were left in the cohort. Furthermore, since 17-OHPC was not shown to be effective for women 
with multiple gestations, and its efficacy for women with short cervix was inconclusive, 15,755 
women with multiple gestations, and 41,693 women with short cervix, cervix incompetence, 
or receiving cerclage surgery were excluded from the sample. To evaluate the adherence and 
effectiveness of 17-OHPC, it is necessary to make sure that each patient had delivery outcomes 
recorded in the database, and the delivery took place between 3 months and 9 months after 
their index date. In addition, a 6-month pre-index period was applied. After all criteria were 
applied 23,911 women were eligible to be included in this study. The patient attrition process 




Figure 4. 1 Patient Attrition Flowchart in DRG databases 
 
  216,609 patients had a history of PTB 
216,160 patients were female 
215,217 women age >16 and <50 
 199,462 women had singleton 
pregnancy 
157,769 women had singleton 
gestations without short cervix 
41,693(19.25%) women had short cervix, 
cervix incompetence or cerclage 
 
23,911 women were eligible to be 
included in the study 
 
108,766(50.21%) women did not have 
delivery outcome recorded between 3 and 
9 months post the index date 
2,051 women used 17-OHPC 
449 (0.21%) patients were male 
943 (0.44%) women age <16 or >50 
15,755 (7.27%) women had multiple 
gestations 
21,860 women did not use 17-OHPC 
49,003 women have delivery outcome 
recorded between 3 and 9 months post 
the index date 
 25,092 (11.58%) women did not have 6 




4.2 Description of Patients’ Demographic and Clinical Characteristics  
The mean age for the sample was 29.3 (SD 5.6) years of age. Patient age was sorted 
into 7 groups, with a 5-year range for each group. Approximately 60% of the sample was 
between 25 and 34 years old, while only 2.16% were between 16 and 20, and 3.82% were 
between 40 and 50. The insurance types were categorized into Medicaid, commercial insurance, 
and ‘other’ insurance. The other insurance category included Medicare, CHAMPUS, self-pay, 
etc. Patients enrolled in commercial insurance accounted for 64.49% of the total sample, 
followed by Medicaid patients (32.66%). In terms of the race/ethnicity, 84.12% of patients had 
missing race/ethnicity coding, and, thus, the bivariate analysis was not conducted for the 
relationship between 17-OHPC utilization and race/ethnicity. Since the geographic distribution 
of patients covered by the DRG database was unequal, the high-risk pregnant women included 
in this study were also unequally distributed in different areas. Patients residing in the 
Southwest U.S. accounted for a large proportion of the sample (34.34%), which was followed 
by the Midwest (24.46%), Northwest (15.71%), Southwest (10.05%), and West (6.19%) 
regions.  
In addition to the demographic characteristics, patients’ baseline clinical characteristics 
were also examined. The sample had a mean CCI score of 0.54 (SD 0.78), with 61.34% having 
no comorbidities. Diagnoses indicating patients with issues of alcohol, tobacco, or drug abuse 
were also analyzed, and 14.79% of the sample had at least one of the three conditions. A 
summary of the sample’s demographic and baseline clinical characteristics is presented in Table 
4.1.   
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Table 4. 1 Demographic and Baseline Clinical Characteristics of the Sample 
Baseline Characteristics Number 
(n=23,911)  
Percent (%) 
Age group Mean±SD 29.34±5.58 
16-19      516   2.16 
20-24   4,714 19.71 
25-29   7,304 30.55 
30-34   6,834 28.58 
35-39   3,629 15.18 
40-50      914   3.82 
Insurance type Medicaid   7,810 32.66 
Commercial  15,467 64.49 
Others      634   2.65 
Race/Ethnicity White   2,463 10.30 
Asian        81   0.34 
Black      999   4.18 
Hispanic or Latino      152   0.64 
Other      102   0.43 
Null/Missing 20,114 84.12 
Geographic region Northeast   3,756 15.71 
Midwest   5,847 24.46 
West   1,479   6.19 
Southeast   8,211 34.34 
Southwest   2,404 10.05 
Null/Missing   2,212   9.25 
Diabetes Yes   1,307   5.47 
No 22,604 94.53 
Hypertension Yes   2,578 10.78 
No 21,333 89.22 
CCIa Mean±SD 0.54±0.78 
0 14,667 61.34 
1   6,333 26.49 
2   2,186   9.14 
>3                 725   3.03 
Alcohol, tobacco, or 
drug abuse 
Yes   3,537 14.79 
No            20,374 85.21 
a CCI= Charlson Comorbidity Index 
The post-index clinical characteristics of the sample were described in Table 4.2. Post-
index diabetes included type I diabetes, type II diabetes, and gestational diabetes (GDM); and 
9.7% of the sample had diagnoses of diabetes after the index date. Post-index hypertension 
included normal hypertension, gestational hypertension (GHT), and preeclampsia; and 20% of 
the sample had diagnoses of hypertension after the index date. Compared to the baseline mean 
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CCI score, the post-index CCI score was higher, which was 0.92 (SD 1.02). The proportion of 
patients without any comorbidity decreased from 61.34% to 42.83%, and the proportion of 
patients with at least three comorbidities increased from 3.03% to 7.79%.  
Table 4. 2 Description of Post-index Clinical Characteristics of the Sample  
Clinical Variables Number 
(n=23,911)  
Percent (%) 
Diabetes a Yes   2,322   9.71 
No 21,589 90.29 
Hypertension b Yes   4,974 20.80 
No 18,937 79.20 
CCI c Mean±SD 0.92±1.02 
0 10,240 42.83 
1   7,896 33.06 
2   3,913 16.36 
>3   1,862   7.79 
Alcohol, tobacco, or 
drug abuse 
Yes   4,962 20.75 
No 18,949 79.25 
a Gestational diabetes was included  
b Gestational hypertension and preeclampsia were included 
c CCI= Charlson Comorbidity Index 
4.3 Utilization of 17-OHPC 
4.3.1 Utilization Rate of 17-OHPC  
Among 23,911 women with a singleton delivery outcome who were eligible to use of 
17-OHPC, less than ten percent (2,051 (8.58%)) had least one claim for 17-OHPC. When the 
utilization rate was examined by the index year, we found the utilization rate showed an 




Table 4. 3 Utilization Rate of 17-OHPC by Year 
Index Year Number of 17-
OHPC Users 
Number of eligible 
17-OHPC Users 
Percent of 17-OHPC 
Utilization (%) 
2012            15 269 5.58 
2013          318 5,497 5.78 
2014          689 9,412 7.32 
2015          573 5,868 9.76 
2016          260 1,973 13.18 
2017          196 892 21.97 
TOTAL 2012-2017             2,051 23,911 8.58 
4.3.2 Comparison of Baseline Characteristics by 17-OHPC Utilization Status  
The mean age for 17-OHPC users and non-17-OHPC users was 29.38 years old and 
29.33 years old, respectively. Given that patients under 20 and those above 35 only accounted 
for a small proportion of the total sample, patients with age 16-19 and 20-24 were merged into 
one group. Similarly, patients with ages equal to or over 35 years were merged into one age 
group. The chi-square test result showed that there was no relationship between patients’ age 
and their utilization status of 17-OHPC (p=0.33). Nonetheless, the utilization rate showed an 
increasing tendency with the increase of patients’ age among patients with age from 16 to 34. 
The utilization rates for patients aged 16-24, 25-29, and 30-34 were 8.08%, 8.79%, and 8.90%, 
respectively. However, the rate decreased slightly for women who were 35 and above. 
In terms of the relationship between insurance type and 17-OHPC utilization status, a 
significant difference in the 17-OHPC utilization rate was observed. Compared to the 
utilization rate among patients enrolled in Medicaid (7.16%) and commercial insurances 
(9.17%), the “Others” group had the highest utilization rate (11.51%). The reason for the high 
utilization rate in the ‘Other’ category was further investigated; and it was noted that patients 
with CHAMPUS (renamed TRICARE) insurance had a much higher utilization rate (33.73%) 
than women with other insurance plans. By further examining the national provider identifiers 
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of patients with CHAMPUS insurance, it was found that the majority of 17-OHPC injections 
were prescribed by two providers from the same state. It is possible that these two providers 
highly support the use of 17-OHPC.  If the utilization rate was only compared between patients 
with Medicaid and commercial insurances, patients with commercial insurances were shown 
to be higher utilizers of 17-OHPC (p<0.0001).  
The utilization rate of 17-OHPC was shown to be significantly different for women in 
different areas of the US (p<0.0001). The highest utilization rate was 12.65% in the Southwest 
area, following by 9.95% in the Midwest area, and the lowest utilization rate in the Northeast 
area (4.61%). 
The association between 17-OHPC utilization and patients’ comorbidities was also 
examined. A total of 1,307 (5.5%) patients had a diagnosis for diabetes before the index date. 
Patients with a pre-index diagnosis for diabetes accounted for 5.47% of non-17-OHPC users 
and 5.41% of 17-OHPC users. A total of 2,578 (10.78%) patients were diagnosed with 
hypertension before the index date; 10.87% of non-17-OHPC users had diagnoses of 
hypertension, which seemed to be slightly higher than that among 17-OHPC users (9.85%). 
However, neither pre-index diabetes (p=0.91) nor pre-index hypertension (p=0.15) diagnoses 
were found to be related with patients’ use of 17-OHPC. Moreover, the utilization rate was 
shown to be unrelated with the CCI score (p=0.42). Additionally, patients without a diagnosis 
for abuse of tobacco, alcohol, or drugs were more likely to use 17-OHPC (8.73%) than women 
with these conditions (7.72%) (p=0.048).  
The comparison of patients’ baseline characteristics by 17-OHPC utilization is 
summarized in Table 4.4. 
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p Value a 
Age group   0.33 
16-24   4,809 (22.00)   421 (20.53)  
25-29   6,662 (30.48)   642 (31.30)  
30-34   6,226 (28.48)   608 (29.64)  
 35   4,163 (19.04)   380 (18.53)  
Insurance type   <0.0001 
Medicaid   7,251 (33.17)           559 (27.25)  
Commercial  14,048 (64.26)        1,419 (69.19)  
Others              561   (2.57)             73   (3.56)  
Geographic region   <0.0001 
Northeast    3,583 (16.39)           173   (8.43)  
Midwest    5,267 (24.09)           582 (28.38)  
West    1,365   (6.24)           114   (5.56)  
Southeast    7,562 (34.59)           649 (31.64)  
Southwest           2,100   (9.61)           304 (14.82)  
Null/Missing           1,983   (9.07)           229 (11.17)  
Diabetes   0.91 
Yes    1,196   (5.47)           111   (5.41)  
No  20,664 (94.53)        1,940 (94.59)  
Hypertension   0.15 
Yes           2,376 (10.87)           202   (9.85)  
No         19,484 (89.13)        1,849 (90.15)  
CCI b   0.42 
0         13,412 (61.35)        1,255 (61.19)  
1           5,799 (26.53)           534 (26.04)  
2           1,980   (9.06)           206 (10.04)  
>3              669   (3.06)             56   (2.73)  
Alcohol, tobacco, or 
drug abuse 
  0.048 
Yes           3,264 (14.93)           273 (13.31)  
No         18,596 (85.07)        1,778 (86.69)  
a p values were determined by cross-tabulations with chi square analysis, significant at p<0.05 (in bold) 




4.4 Medication Adherence 
4.4.1 Evaluation of Medication Adherence 
Of the 2051 women prescribed 17-OHPC, 407 (19.84%) were adherent using our 
definition of adherence. Patients were considered to be adherent if they received >10 injections, 
and their number of injections divided by the maximum number of weeks recommended was 
greater than 0.7. The average number of injections the patients received was 7.50 (SD 6.01). A 
sensitivity analysis using a less stringent definition of medication adherence was also 
conducted. In the sensitivity analysis, patients receiving no less than 10 injections were 
categorized as adherers. Under this definition, 686 (33.45%) of users were adherent to 17-
OHPC.  
4.4.2 Comparison of Patients’ Characteristics by 17-OHPC Adherence Status 
In order to investigate if patients’ characteristics were associated with their adherence, 
bivariate analyses and the corresponding sensitivity analyses were conducted. The base case 
results and sensitivity analysis results are summarized in Table 4.5 and Table 4.6. The 
adherence rates were 16.63%, 20.40%, 20.23%, and 21.84% for women aged 16-24, 25-29, 30-
34, and  35 years old. No significant difference was found between adherence rate and age 
(p=0.27). A similar trend was also observed in the sensitivity analysis, with adherence rates of 
32.30%, 32.24%, 33.39%, and 36.84% for women aged 16-24, 25-29, 30-34, and  35 years 
old. Similarly, there was no significant difference (p=0.45). 
The adherence rate was significantly different for patients with different insurance plans; 
21.29% of Medicaid patients, 18.32% of commercial insurance patients, and 38.36% of patients 
with other insurances were adherent to 17-OHPC. Similar to the high utilization rate shown in 
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the “Others” group, CHAMPUS patients had a high adherence rate (59.22%) as well, which 
increased the overall adherence rate of the “Others” group. When the comparison was made 
between Medicaid patients and patients enrolled in commercial insurances, even though 
Medicaid patients had a higher adherence rate, there was no statistically significant difference 
(p=0.13). Again, in the sensitivity analysis using the second definition of adherence, patients 
in the “Other” group were most adherent, with a 47.95% adherence rate. However, Medicaid 
patients were significantly more likely to be adherent (37.57%) than commercial insurance 
patients (31.08%) (p=0.01).  
In terms of the association between patients’ post-index comorbidities and adherence, 
no relationship was found between adherence to 17-OHPC and diabetes (p=0.63), hypertension 
(p=0.84), or CCI score (p=0.82). No significant difference was found in any sensitivity analyses 
as well. The adherence rate for patients with tobacco, alcohol, or drug abuse diagnoses was 
mathematically lower than those without these conditions (16.20% vs. 20.61%). However, 
there was no statistically significant difference using the original definition (p=0.06), nor the 








Users (N, %) 
(n=1,644) 
Adherent 17-OHPC 
Users (N, %) 
(n=407) 
p Value a 
Age group   0.27 
16-24              351 (21.35)               70 (17.20)  
25-29              511 (31.08)             131 (32.19)  
30-34              485 (29.50)             123 (30.22)  
 35              297 (18.07)               83 (20.39)  
Insurance type   <0.0001 
Medicaid              440 (26.76)             119 (29.24)  
Commercial           1,159 (70.50)            260 (63.88)  
Others                45   (2.74)               28   (6.88)  
Diabetes b   0.63 
Yes              167 (10.16)               47 (11.55)  
No           1,477 (89.84)             360 (88.45)  
Hypertension c   0.84 
Yes              343 (20.86)               87 (21.38)  
No           1,301 (79.14)             320 (78.62)  
CCI d   0.82 
0              728 (44.28)             190 (46.68)  
1              523 (31.81)             127 (31.21)  
2              272 (16.55)               63 (15.48)  
>3              121   (7.36)               27   (6.63)  
Alcohol, tobacco, or 
drug abuse 
  0.06 
Yes              300 (18.25)               58 (14.25)  
No           1,344 (81.75)             349 (85.75)  
a p values were determined by cross-tabulations with chi square analysis, significant at p<0.05 (in bold) 
b Gestational diabetes was included  
c Gestational hypertension and preeclampsia were included 
d CCI=Charlson Comorbidity Index 
* Adherence definition: Patients received > 10 injections, and their number of injections divided by the 










Users (N, %) 
(n=1,365) 
Adherent 17-OHPC 
Users (N, %) 
(n=686) 
p Value a 
Age group   0.45 
16-24   285 (20.88)  136 (19.83)  
25-29   435 (31.87)  207 (30.17)  
30-34   405 (29.67)  203 (29.59)  
 35   240 (17.58)  140 (20.41)  
Insurance type   0.0006 
Medicaid   349 (25.57)  210 (30.61)  
Commercial    978 (71.65)  441 (64.29)  
Others               38   (2.78)              35   (5.10)  
Diabetes b   0.86 
Yes             135   (9.89)    79 (11.52)  
No          1,230 (90.11)  607 (88.48)  
Hypertension c   0.38 
Yes    293 (21.47)  137 (19.97)  
No          1,072 (78.53)  549 (80.03)  
CCI d   0.78 
0    603 (44.18)  315 (45.92)  
1    442 (32.38)  208 (30.32)  
2    220 (16.12)  115 (26.76)  
>3             100   (7.32)              48   (7.00)  
Alcohol, tobacco, or 
drug abuse 
  0.65 
Yes             242 (17.73) 116 (16.91)  
No          1,123 (82.27) 570 (83.09)  
a p values were determined by cross-tabulations with chi square analysis, significant at p<0.05 (in bold) 
b Gestational diabetes was included  
c Gestational hypertension and preeclampsia were included 
d CCI=Charlson Comorbidity Index 
* Adherence definition: patients received >10 injections. 
4.5 PTB and 17-OHPC Utilization 
Patients’ baseline characteristics were compared by their delivery outcome (whether 
they had a PTB or not). The results are shown in Table 4.7. It is noted that except for post-index 
diabetes (p=0.3), the other characteristics were all shown to be associated with whether the 
women have PTB or not. In terms of age, the PTB rate for women aged 16-24, 25-29, 30-34, 
and  35 years old were 16.39%, 14.14%, 12.36%, and 11.64%, respectively, which suggested 
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that younger women, especially women younger than 25 years, were more likely to have a PTB 
(p<0.0001). Women with Medicaid insurance were more likely to have a PTB than those with 
commercial and other insurances (p<0.0001). The geographic region was also associated with 
PTB (p<0.0001), with the Northeast area showing the highest PTB rate (15.55%), followed by 
the Southeast area (13.93%) and the Southwest area (13.48%). Patients diagnosed with 
hypertension (p=0.0006), patients with a higher CCI score (p<0.0001), and those diagnosed 
with alcohol, tobacco, or drug abuse conditions (p=0.002) were also shown to be associated 
with higher PTB rate.   
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Table 4. 7 Comparison of Patients’ Characteristics by Delivery Outcome 
Patients’ 
Characteristics 
No PTB (N, %) 
(n=20,647) 
PTB (N, %) 
(n=3,264) 
p Value a 
Age group   <0.0001 
16-24  4,373 (21.18)          857 (26.26)  
25-29  6,271 (30.37)       1,033 (31.65)  
30-34  5,989 (29.01)          845 (25.89)  
 35  4,014 (19.44)          529 (16.21)  
Insurance type   <0.0001 
Medicaid  6,668 (32.30)       1,142 (34.99)  
Commercial        13,398 (64.89)       2,069 (63.39)  
Others     581   (2.81)            53   (1.62)  
Geographic region   <0.0001 
Northeast  3,172 (15.36)          584 (17.89)  
Midwest  5,062 (24.52)          787 (24.11)  
West          1,289   (6.24)          190   (5.82)  
Southeast  7,067 (34.23)       1,144 (35.05)  
Southwest  2,080 (10.07)          324   (9.93)  
Null/Missing          1,977   (9.58)          235   (7.20)  
Diabetes   0.3022 
Yes          2,037   (9.64)          285   (9.07)  
No        18,610 (90.36)       2,979 (90.93)  
Hypertension   0.0006 
Yes  4,250 (20.11)          724 (22.73)  
No        16,397 (78.89)       2,540 (77.27)  
CCI b   <0.0001 
0  8,952 (43.36)       1,288 (39.46)  
1  6,815 (33.01)       1,081 (33.12)  
2  3,314 (16.05)          599 (18.35)  
>3          1,566   (7.58)          296   (9.07)  
Alcohol, tobacco, or 
drug abuse 
  0.0023 
Yes  4,219 (20.43)          743 (22.76)  
No        16,428 (79.57)       2,521 (77.24)  
a p values were determined by cross-tabulations with chi square analysis, significant at p<0.05 (in bold) 
b CCI=Charlson Comorbidity Index 
Chi-square tests were conducted to investigate the association between use of 17-OHPC 
and PTB rate, as well as the relationship between 17-OHPC adherence and PTB rate. The 
results are presented in Table 4.8 and Table 4.9. The PTB rate was lower among non-17-OHPC 
users (13.61%) than 17-OHPC users (14.04%). However, no significant difference was found 
between the use of 17-OHPC and PTB rate (p=0.59). Among 17-OHPC users, the PTB rate 
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was higher among adherers than non-adherers (15.48% vs. 13.69%), but this was not 
statistically different (p=0.35). Since the covariates were not controlled in the bivariate analysis, 
17-OHPC users and especially those adherent users may be determined to be at higher risk at 
the index date than those who did not use 17-OHPC. The comparison of the PTB rate was also 
made among non-users, adherent users, and non-adherent users (p=0.55), and the results are 
presented in Table 4.10.  
Table 4. 8 Comparison of PTB Rate by Utilization Status of 17-OHPC 
PTB Non-17-OHPC 





p Value a 
Yes   2,976 (13.61) 288 (14.04) 0.59 
No 18,884 (86.39)  1,763 (85.96)  
a p values were determined by cross-tabulations with chi square analysis, significant at p<0.05 
 
Table 4. 9 Comparison of PTB Rate by Adherence Status of 17-OHPC 
PTB Nonadherent 17-
OHPC Users (N, %) 
(n=1,644) 
Adherent 17-OHPC 
Users (N, %) 
(n=407) 
p Value a 
Yes 225 (13.69)   64 (15.48) 0.35 
No 1,419 (86.31) 344 (84.52)  
a p values were determined by cross-tabulations with chi square analysis, significant at p<0.05 
* Adherence definition: patients received >10 injections, and their received number of injections divided 
by the maximum number of weeks that patients should get injections is greater than 0.7 
 
Table 4. 10 Comparison of PTB Rate by Utilization and Adherence Status of 17-OHPC 
PTB  Non-17-OHPC 










p Value a 
Yes   2,976 (13.61) 255 (13.69)   63 (15.48) 0.55 
No 18,884 (86.39) 1,419 (86.31) 344 (84.52)  
a p values were determined by cross-tabulations with chi square analysis, significant at p<0.05 
* Adherence definition: patients received >10 injections, and their received number of injections divided 
by the maximum number of weeks that patients should get injections is greater than 0.7 
In the sensitivity analysis using the alternative definition of adherence, there is still no 
difference in PTB rate found between adherers and non-adherers (p=0.35). Using this less 
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stringent way to define medication adherence, we found very similar rates of PTB between 
adherers (13.99%) and non-adherers (14.07%) (See Table 4.11 and Table 4.12).  
Table 4. 11 Sensitivity Analysis of Comparison of PTB Rate by Utilization and Adherence 
Status of 17-OHPC  
PTB Nonadherent 17-
OHPC Users (N, %) 
(n=1,365) 
Adherent 17-OHPC 
Users (N, %) 
(n=686) 
p Value a 
Yes 192 (14.07)   96 (13.99) 0.96 
No 1,173 (85.93) 590 (86.01)  
a p values were determined by cross-tabulations with chi square analysis, significant at p<0.05  
* Adherence definition: patients received >10 injections. 
 
Table 4. 12 Sensitivity Analysis of Comparison of PTB Rate by Utilization and Adherence 
Status of 17-OHPC 
PTB  Non-17-OHPC 










p Value a 
Yes   2,976 (13.61) 192 (14.07)   96 (13.99) 0.86 
No 18,884 (86.39) 1,173 (85.93) 590 (86.01)  
a p values were determined by cross-tabulations with chi square analysis, significant at p<0.05 
* Adherence definition: patients received >10 injections. 
A logistic regression was also conducted to investigate the relationship between the 
utilization and adherence status of 17-OHPC and the incidence of PTB. The results showed 
that there is still no significant difference in PTB rate between non-17-OHPC users and non-
adherent users (OR=1.04, 95% CI=0.90-1.20), and adherent users (OR=1.26, 95% CI=0.96-
1.65) after controlling the covariates. Holding the other covariates constant, older patients aged 
25-29, 30-35, and >35 were 17% (OR=0.83, 95% CI=0.72-0.92), 28% (OR=0.72, 95% 
CI=0.64-0.79), and 34% (OR=0.66, 95% CI=0.59-0.74) less likely to have PTB than patients 
aged <25, respectively; patients residing in the Southeast area were 12% less likely to have 
PTB (OR=0.88, 95% CI=0.79-0.98) than Northeast patients; patients with hypertension were 
15% (OR=1.15, 95% CI=1.02-1.29) more likely to have PTB; patients with CCI of 1, 2, or >3 
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were 10% (OR=1.10, 95% CI=1.01-1.20), 26% (OR=1.26, 95% CI=1.14-1.41), and 35% 
(OR=1.35, 95% CI=1.17-1.56) more likely to have PTB than patients with CCI of 0. However, 
no significant difference in the incidence of PTB was observed between patients with 
commercial insurance and Medicaid patients (OR=0.95, 95% CI=0.87-1.03), between patients 
with and without diabetes (OR=1.17, 95% CI=1.00-1.38), and between patients with and 
without diagnoses of alcohol, tobacco, or drug abuse (OR=1.04, 95% CI=0.95-1.14). The 
results are shown in Table 4.13. 
Table 4. 13 Logistic Regression of Incidence of PTB by Patients’ Utilization and 
Adherence Status of 17-OHPC 
Variables OR 95% CI Wald X2 p Value a 
Utilization and adherence status of 17-OHPC 
Non-adherent users 1.04  0.90-1.20  0.58 0.4451 
Adherent users 1.26  0.96-1.65  2.18 0.1402 
Covariates 
Age  
25-29 0.83  0.72-0.92  2.45 0.1175 
30-35 0.72 0.64-0.79  9.49 0.0021 
>35 0.66 0.59-0.74 22.16    <0.0001 
Insurance type  
Commercial          0.95     0.87-1.03          8.84      0.0030 
Others          0.56     0.42-0.75        14.05      0.0002 
Geographic region  
Midwest 0.82 0.73-0.92  0.01 0.9201 
West 0.81 0.68-0.97  0.01 0.9064 
Southeast 0.88 0.79-0.98  4.02 0.0450 
Southwest 0.80 0.69-0.93  0.14 0.7138 
Null/Missing 0.64 0.54-0.75 16.44    <0.0001 
Diabetes 1.17 1.00-1.38 3.93 0.0475 
Hypertension 1.15 1.02-1.29 5.04 0.0247 
CCI  
CCI=1 1.10 1.01-1.20  3.87 0.0493 
CCI=2 1.26 1.14-1.41  3.97 0.0464 
CCI>3 1.35 1.17-1.56  7.94 0.0048 
Alcohol, tobacco, or 
drug abuse 
1.04 0.95-1.14  0.74 0.3892 
a p values were determined by cross-tabulations with chi square analysis, significant at p<0.05  
OR=odds ratio; CI=confidence interval; X2=Chi-square; CCI=Charlson Comorbidity Index   
Reference categories: non-17-OHPC users; aged <=25; Medicaid insurance; Northeast geographic 
region; CCI=0; With diagnoses of alcohol, tobacco or drug abuse  
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4.6 Incidence of Diabetes and Hypertension and 17-OHPC Utilization 
The relationship between 17-OHPC utilization and the incidence of diabetes (including 
GDM) and hypertension (including GHT and preeclampsia) were investigated using chi-square 
tests. In this case, the patients with new diagnoses of diabetes or hypertension after the index 
date were included in the analysis. The results are summarized in Table 4.14, showing that 5.68% 
of non-users and 5.02% of users had a post-index diagnosis of diabetes with no pre-index code 
for the condition. No significant association was found between 17-OHPC utilization and 
incidence of new diabetes diagnosis (p=0.21). In terms of the incidence of hypertension, 13.08% 
of non-users and 11.12% of users were newly diagnosed with hypertension after the index date. 
Furthermore, 17-OHPC users were significantly less likely to have a new hypertension 
diagnosis than the non-users (p=0.01). 







17-OHPC Users  
(N, %) 
(n=2,051) 
p Value a 
Diabetes b   0.21 
Yes             1,242   (5.68)              103   (5.02)  
No           20,618 (94.32)    1,948 (94.98)  
Hypertension c   0.01 
Yes             2,859 (13.08) 228 (11.12)  
No           19,001 (86.92) 1,823 (88.88)  
a p values were determined by cross-tabulations with chi square analysis, significant at p<0.05 (in bold) 
b Gestational diabetes was included  
c Gestational hypertension and preeclampsia were included 
The association between 17-OHPC adherence and incidence of diabetes or 
hypertension was also examined. Among adherers, 5.65% were newly diagnosed with diabetes 
and 11.79% were newly diagnosed with hypertension, both of which are higher than that for 
non-adherers, with 4.87% newly diagnosed with diabetes and 10.95% newly diagnosed with 
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hypertension (See Table 4.15). However, adherence of 17-OHPC was not found to be 
significantly related to incidence of diabetes (p=0.52), nor incidence of hypertension (p=0.62). 
No significant difference was found in the sensitivity analyses as well (See Table 4.16). 





Users (N, %) 
(n=1,644) 
Adherent 17-OHPC 
Users (N, %) 
(n=407) 
p Valuea 
Diabetes b   0.52 
Yes                80   (4.87)             23   (5.65)  
No           1,564 (95.13)  384 (94.35)  
Hypertension c   0.62 
Yes    180 (10.95)    48 (11.79)  
No 1,464 (89.05)  359 (88.21)  
a p values were determined by cross-tabulations with chi square analysis, significant at p<0.05 
b Gestational diabetes was included  
c Gestational hypertension and preeclampsia were included 
* Adherence definition: patients received >10 injections, and their received number of injections divided 
by the maximum number of weeks that patients should get injections is greater than 0.7 
 
Table 4. 16 Sensitivity Analysis of Relationship Between 17-OHPC Adherence and 




Users (N, %) 
(n=1,365) 
Adherent 17-OHPC 
Users (N, %) 
(n=686) 
p Valuea 
Diabetes b   0.16 
Yes                62   (4.54)             41   (5.98)  
No           1,303 (95.46)  645 (94.02)  
Hypertension c   0.85 
Yes              153 (11.21)    75 (10.93)  
No 1,212 (88.79)  611 (10.93)  
a p values were determined by cross-tabulations with chi square analysis, significant at p<0.05  
b Gestational diabetes was included  
c Gestational hypertension and preeclampsia were included 
* Adherence definition: patients received >10 injections. 
When the incidence rate of diabetes was compared among non-users, adherent users, 
and non-adherent users, no association was found between use of 17-OHPC and incidence of 
diabetes in both the base case (p=0.38) and the sensitivity analysis (p=0.19). As for 
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hypertension, the use of 17-OHPC was associated with a lower incidence rate of hypertension 
(p=0.04). However, the result may not indicate a ‘practical’ difference from the clinical point 
of view. The results were shown in Table 4.17 and 4.18. 
Table 4. 17 Relationship Between Utilization and Adherence Status of 17-OHPC and 














p Value a 
Diabetes b    0.38 
Yes     1,242   (5.68)         80   (4.87)       23   (5.65)  
No   20,618 (94.32)    1,564 (95.13)     384 (94.35)  
Hypertension c    0.04 
Yes     2,859 (13.08)       180 (10.95)       48 (11.79)  
No   19,001 (86.92)    1,464 (89.05)     359 (88.21)  
a p values were determined by cross-tabulations with chi square analysis, significant at p<0.05 (in bold) 
b Gestational diabetes was included  
c Gestational hypertension and preeclampsia were included 
* Adherence definition: patients received >10 injections, and their received number of injections divided 
by the maximum number of weeks that patients should get injections is greater than 0.7 
 
Table 4. 18 Sensitivity Analysis of Relationship Between Utilization and Adherence Status 














p Value a 
Diabetes b    0.19 
Yes     1,242   (5.68)         62   (4.54)       41   (5.98)  
No   20,618 (94.32)    1,303 (95.46)     645 (94.02)  
Hypertension c    0.04 
Yes     2,859 (13.08)       153 (11.21)       75 (10.93)  
No   19,001 (86.92)    1,212 (88.79)     611 (89.07)  
a p values were determined by cross-tabulations with chi square analysis, significant at p<0.05 (in bold) 
b Gestational diabetes was included  
c Gestational hypertension and preeclampsia were included 
* Adherence definition: patients received >10 injections. 
A summary of study objectives, hypotheses, statistical tests, and corresponding results 
is presented in Table 4.19. 
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Objectives Hypotheses Statistical Analysis Testing 
Results 
1)   To describe patients’ 
baseline characteristics 
N/A Descriptive statistics 
(i.e. mean, standard 
deviation, frequency) 
N/A 
2)  To describe 17-
OHPC utilization, and 
compare baseline 
characteristics by 
utilization status of 17-
OHPC 
H02a: There is no significant difference in age between high PTB risk 
pregnant women with and without 17-OHPC. 
Chi-square test; 
 
Failed to reject 
H02b: There is no significant difference in insurance type between high 
PTB risk pregnant women with and without 17-OHPC. 
Rejected 
H02c: There is no significant difference in geographic region between 
high PTB risk pregnant women with and without 17-OHPC. 
Rejected 
H02d: The initiation of 17-OHPC is not significantly related to whether 
pregnant women with high PTB risk had pre-index diabetes or not. 
Failed to reject 
H02e: The initiation of 17-OHPC is not significantly related to whether 
pregnant women with high PTB risk had pre-index hypertension or 
not. 
Failed to reject 
H02f: There is no significant difference in proportion of different pre-
index CCI score between high PTB risk pregnant women with and 
without 17-OHPC. 
Failed to reject 
H02g: The initiation of 17-OHPC is not significantly related to whether 
pregnant women with high PTB risk had pre-index diagnoses of 
alcohol, tobacco, or drug abuse or not. 
Rejected 
3)  To assess medication 
adherence of women 
receiving 17-OHPC 
N/A Descriptive statistics 















Objectives Hypotheses Statistical Analysis Testing 
Results 
4)   To compare patients’ 
characteristics by 





H04a:  There is no significant difference in age between high PTB risk 
pregnant women with and without adequate medication adherence. 
Chi-square test; 
 
Failed to reject 
H04b:  There is no significant difference in insurance type between high 
PTB risk pregnant women with and without adequate medication 
adherence. 
Rejected 
H04c: There is no significant difference in proportion of post-index 
diabetes between high PTB risk pregnant women with and without 
adequate medication adherence. 
Failed to reject 
H04d: There is no significant difference in proportion of post-index 
hypertension between high PTB risk pregnant women with and without 
adequate medication adherence. 
Failed to reject 
H04e:  There is no significant difference in proportion of different post-
index CCI score between high PTB risk pregnant women with and 
without 17-OHPC. 
Failed to reject 
H04f: There is no significant difference in proportion of post-index 
diagnoses of alcohol, tobacco, or drug abuse between high PTB risk 
pregnant women with and without 17-OHPC. 
Failed to reject 
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Objectives Hypotheses Statistical Analysis Testing 
Results 
5)  To compare patients’ 
characteristics by 
delivery outcome  
H05a: There is no significant difference in age between high PTB risk 




H05b: There is no significant difference in insurance type between high 
PTB risk pregnant women with and without PTB. 
Rejected 
H05c: There is no significant difference in geographic region between 
high PTB risk pregnant women with and without PTB. 
Rejected 
H05d: There is no significant difference in proportion of post-index 
diabetes diagnoses between high PTB risk pregnant women with and 
without PTB 
Failed to reject 
H05e: There is no significant difference in proportion of post-index 
hypertension diagnoses between high PTB risk pregnant women with 
and without PTB 
Rejected 
H05f: There is no significant difference in proportion of different post-
index CCI score between high PTB risk pregnant women with and 
without PTB. 
Rejected 
H05g: There is no significant difference in proportion of post-index 
alcohol, tobacco, or drug abuse diagnoses between high PTB risk 




Table 4.19 (continued) 
 
Objectives Hypotheses Statistical Analysis Testing 
Results 
6)  To compare delivery 
outcome by utilization 
and adherence status of 
17-OHPC 
H06a: There is no significant difference in PTB rate between high PTB 
risk pregnant women with and without 17-OHPC. 
Chi-square test;  
 
Failed to reject 
H06b: There is no significant difference in PTB rate between high PTB 
risk pregnant women with and without adequate medication adherence. 
Failed to reject 
H06c: There is no association between PTB rate and utilization and 
adherence status of high PTB risk pregnant women (non-17-OHPC 
users, adherers, non-adherers). 
Failed to reject 
H06d: There is no association between PTB rate and utilization and 
adherence status of high PTB risk pregnant women (non-17-OHPC 
users, adherers, non-adherers), controlling for covariates. 
Logistic regression Failed to reject 
7) To determine if 
utilization and adherence 
status 17-OHPC is 
related to incidence of 
diabetes (including 
GDM) or hypertension 
(including GHT or 
preeclampsia). 
H07a: The use of 17-OHPC is not significantly associated with the 
incidence of diabetes.  
Chi-square test 
 
Failed to reject 
H07b: The adherence of 17-OHPC is not significantly associated with 
the incidence of diabetes.  
Failed to reject 
H07c: The incidence of diabetes is not significantly associated with 
utilization and adherence status of 17-OHPC (non-17-OHPC users, 
adherers, non-adherers). 
Failed to reject 
H07d: The use of 17-OHPC is not significantly associated with the 
incidence of hypertension. 
Rejected 
H07e: The adherence of 17-OHPC is not significantly associated with 
the incidence of hypertension. 
Failed to reject 
H07f: The incidence of hypertension is not significantly associated with 





Chapter 5 Discussion 
5.1 Chapter Overview 
This chapter provides a review of the study purpose and a detailed discussion of the study 
results for each objective. Possible explanations of the results and comparisons with results of a 
Texas Medicaid database analysis and other studies are provided. The strengths and limitations of 
the study are also discussed in this chapter. Lastly, the major conclusions and recommendations 
for future studies are provided. 
5.2 Study Purpose 
The main purpose of this study was to investigate the utilization, adherence, and 
effectiveness of 17-OHPC. Patients’ characteristics that may be associated with 17-OHPC 
utilization and adherence status were investigated, which included age, insurance type, geographic 
region, comorbidities, and tobacco, alcohol, or drug abuse. The relationships between 17-OHPC 
utilization and incidence of maternal complications, including gestational diabetes (GDM), 
gestational hypertension (GHT), and preeclampsia were also examined in the study. 
5.3 Study Objectives 
5.3.1 Objective 1 and 2: Utilization of 17-OHPC and patients’ characteristics 
In this study, less than ten percent (8.58%) of women at risk for recurrent PTB who met 
criteria received 17-OHPC from 2012 to 2017. This number is higher than that was reported by 
the Louisiana Department of Health and Hospitals (4.67% in 2011 and 7.41% in 2013).110 However, 
the utilization rates in the DRG database increased each year, from 5.58% of eligible women in 
2012, to 7.32% in 2014, which is consistent with that among Louisiana Medicaid patients. The 
utilization rate in the DRG cohort continued to increase to 9.76% in 2015, 13.18% in 2016, and 
21.97% in 2017, which may reflect a growing trend in its use. By applying the same inclusion and 
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exclusion criteria, similar objectives were also investigated among Texas Medicaid cohorts from 
July 1, 2013 to June 30, 2015. The patient attrition process for this analysis is shown in Appendix 
Figure A.1. In the Texas Medicaid database, we found that 585 out of 3,541 eligible women 
(16.52%) used 17-OHPC (unpublished internal report). Although the utilization rate in Texas 
Medicaid was higher than the average utilization rate of DRG cohorts, it should be noted that the 
average utilization rate in the Southwest area (12.65%) of the DRG cohort was shown to be the 
highest across the country. In addition, this number is consistent with the findings of Cross-Barnet 
et al. (2018). This study was conducted by the Center for Medicare and Medicaid Innovation, 
which launched Strong Start programs from 2013 to 2017, and 27 awardees from over 200 sites in 
30 states participated. They reported that 14.95% of 45,999 eligible enrolled patients received 17-
OHPC.135  
Generally, the utilization rate of 17-OHPC is still low, and factors that may be associated 
with utilization rates were investigated. According to our results, among the investigated 
demographic and clinical characteristics, age and medical comorbidities were not associated with 
the use of 17-OHPC. This is consistent with other studies. Similar results were found in the Texas 
Medicaid database, as neither patients’ age (p=0.39) nor their race/ethnicity (p=0.14) was related 
to 17-OHPC utilization (See Appendix Table A.1 and Table A.2). No association between the use 
of 17-OHPC and patients’ medical comorbidities was reported in DeNoble et al.’s study either.115  
Patients’ insurance type, geographic region, and alcohol, tobacco, or drug abuse were 
shown to be related to the use of 17-OHPC. In terms of patients’ insurance type, patients with 
commercial insurance were more likely to use 17-OHPC than Medicaid patients. This finding is 
consistent with Berhie et al.’s study, which found that women enrolled in public insurance were 
less likely to have 17-OHPC prescribed than privately insured patients (aOR = 0.39, 95% CI = 
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0.19-0.82).120 One possible reason for the low utilization rate among public insurance patients is 
the administrative burden of preauthorization. Preauthorization is often required when 17-OHPC 
is prescribed, and, thus, women who were indecisive about the intervention or who initiated 
prenatal care late in their pregnancy may be further delayed by this extra step.120 From a provider’s 
perspective, different insurance plans have different processes and protocols of prior approval, 
which can consume a large amount of a prescriber’s time. Thus, they may prefer to write a 
prescription for vaginal progesterone instead of spending time initiating an application for 
preauthorization.135 Thus, variations in Medicaid and other insurance policies regarding the 
coverage and reimbursement of 17-OHPC may still be a barrier to patient access.108  
In addition to insurance hurdles, other reported factors that were not included in the DRG 
database but have been previously associated with 17-OHPC underutilization included women’s 
earliest PTB at greater gestational age,115,136 delay in prenatal care initiation,115,135 and Hispanic 
ethnicity.115 Barriers of 17-OHPC uptake were also explored by qualitative studies from both the 
patient and provider perspectives. From the patient perspectives, the main barriers included 
unknown complications, concerns about safety, lack of information, time commitment, unstable 
housing, lack of childcare, and job inflexibility.120,136 As for time commitment, patients were 
bothered more by the length of individual appointments, instead of the weekly injection routine.136 
Other provider-perceived barriers to patients’ receipt of 17-OHPC included “financial barriers,” 
“fear of injections,” and “difficulty in arranging injections.”137 From the provider perspective, “the 
cost risks to provider,” “‘non-physician providers’ practice scope limitations,” and “the time-
consuming preauthorization application process” are thought to be major barriers to prescribing 
17-OHPC.135 In addition, “concerns about neonatal untoward effects” and the “high cost of 
Makena” were pointed out in another online survey as barriers to prescribing 17-OHPC.138 The 
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initial acquisition cost of branded 17-OHPC (Makena) was set at $1440 per injection; thus, the 
total cost for 20 injections would be about $30,000 per pregnancy.139  
Facilitators of 17-OHPC utilization were also explored, including a universal insurance 
authorization process, options for home administration, and effective communication between 
patients and providers.135 In addition, the active role of state and territorial health agencies in 
promoting the access and use of 17-OHPC is an important facilitator. Four main approaches that 
have been suggested are: 1) use databases to promote early identification of eligible women; 2) 
simplify the ordering process; 3) reimburse a woman’s transportation to clinic appointments or 
offer home injections; and 4) inform providers and patients about the efficacy of 17-OHPC and 
clarify the reimbursement policies.109 Several states, including Louisiana, North Carolina, Ohio, 
Texas, Iowa, and South California, are taking various approaches to promote the utilization of 17-
OHPC, which may explain why the utilization rate of 17-OHPC is higher in the Southwest, 
Midwest, and Southeast regions of the U.S. 
5.3.2 Objective 3 and 4: 17-OHPC Adherence and patients’ characteristics 
Two definitions were applied to evaluate patients’ adherence to 17-OHPC in this study. By 
defining patients with at least 10 injections and 70% of their possible maximum number of 
injections as the minimum threshold, the adherence rate was 19.84%, which is close to the 
adherence rate of the Texas Medicaid cohort (18.97%), when applying the same adherence 
definition. In the sensitivity analysis, a less strict criterion was applied (patients receiving at least 
10 injections were considered to be adherent), and the adherence rate was still only 33.45% among 
the DRG cohort and 29.40% among the Texas Medicaid cohort, both lower than that reported in 
other studies. However, it is noteworthy that no consistent definition was applied to evaluate 17-
OHPC adherence across different studies. Studies reporting a high adherence rate usually had a 
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small sample size of patients from an individual medical institution. Yee et al. reported an 83% 
adherence rate with a sample size of 229 from a single institution.113 DeNoble et al. reported a 
72.2% adherence rate with sample size of 115 patients from a Duke University-affiliated 
hospital.115 
Compared to studies using data from a single institution, the adherence rate was lower 
among studies using state Medicaid databases and national databases. With a sample size of 169, 
an adherence rate of 66.3% among the Massachusetts Medicaid population was reported by 
Hydery et al.117 The adherence rate was 50% for a Louisiana Medicaid population with a larger 
sample size of 745, by defining adherence as receiving at least ten injections (the same as the 
adherence definition in the sensitivity analysis).110 By using data collected from one of Centene’s 
managed Medicaid programs, Lucas et al. found that 58.6% of 790 patients initiated 17-OHPC in 
the recommended gestational age window.116 Carter et al. used MarketScan data and the adherence 
was measured similarly to our base case adherence analysis. The results showed that of 3,374 
patients, 32.3% had an adherence rate over 85%, which is closer to what was reported in this 
study.114 The higher adherence rate reported in studies using data from a single institution may be 
attributable to a higher quality of care received by patients with these providers. On the other hand, 
policies related to 17-OHPC reimbursement and prior authorization processes vary across different 
states. Thus, greater differences in population characteristics and variance in policies exist in the 
national databases compared to one certain individual state Medicaid database and one single 
medical institution.  
In terms of factors related to adherence, only insurance type was found to be associated 
with a patients’ adherence to 17-OHPC in this study. However, the significant difference is 
attributable to high adherence rate in the “others” group (38.36%). By further examining the 
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difference in adherence rates between patients with Medicaid or commercial insurance, no 
significant difference was observed. Similarly, Sutton et al. did not find a relationship between 
adherence and insurance status.119 The other characteristics examined in the study, including age, 
geographic regions, and comorbidities, were not shown to be associated with adherence. For Texas 
Medicaid cohorts, no relationship between adherence and age or race was observed (See Appendix 
Table A.3 and Table A.4). Similarly, race, number of comorbidities, and different types of 
comorbidities were not shown to be associated with adherence in Hydery et al.’s study.117 Carter 
et al. found that except for number of prior PTBs, the other factors, including maternal age and 
different types of comorbidities, were not shown to be related to the timing of 17-OHPC 
initiation.114 However, maternal age was reported to be associated with adherence in several studies. 
DeNoble et al., Sutton et al., and Haidar et al. found that women with older maternal age were 
more likely to be adherent to 17-OHPC.115,118,119 In our study, even though no statistically 
significant association was observed between adherence and age, the adherence rates showed an 
increasing trend for women aged 16-24, 25-29, 30-34, and  35 years old, with adherence rate of 
16.63%, 20.40%, 20.23%, and 21.84%, respectively. It is possible that younger women have more 
access barriers to health care than older women, or may not be skilled enough to navigate the health 
care system.115 In terms of race and ethnicity, Berhie et al.120 and Yee et al.113 stated that non-
Hispanic Black women were less likely to be adherent than White women. The Texas Medicaid 
database analysis also showed that the adherence rate among White women (22.58%) was higher 
than that among Black women (18.33%) and Hispanic women (16.18%), although these 
differences were not statistically significant, and the variable indicating ethnicity was missing for 
the majority of patients. 
Therefore, from the variables that were available from the DRG database, only age was 
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previously shown to possibly be associated with patients’ adherence, although there is no 
consensus. Other factors that may affect patients’ adherence were also investigated by a qualitative 
study or a study using mixed methodologies. Several barriers that were not available in the claims 
database might explain low adherence rates for 17-OHPC. First, some people fear injections, so 
after the first injection, patients may choose to stop receiving them.110 Secondly, perfect adherence 
would consist of approximately 20 continuous injections or more. Such a long-term injection 
timeframe is burdensome for pregnant women. Despite home injections being available, not all 
insurance plans cover this option, so some pregnant women would need to go to their clinic every 
week. Thus, the long-term transportation and time commitment may be a burden that can reduce 
adherence.110 Corresponding to this, two facilitators for participants’ adherence were mentioned in 
previous research: administration location flexibility, and a well-designed work flow among 
entities involved in 17-OHPC provision, administration, and payment.135 Additionally, the high 
cost may prevent people with low socioeconomic status or those with high insurance co-pays from 
being adherent. 
5.3.3 Objective 5 and 6: Effectiveness of 17-OHPC 
The PTB rate was not found to be associated with utilization and adherence status of 17-
OHPC in this study. In the Texas Medicaid cohort, 17-OHPC users, especially the adherent users, 
were more likely to have PTB (p=0.003) (See Appendix Table A.5). However, covariates were not 
controlled in this case, so patients using 17-OHPC may be at higher risk of PTB than non-users. 
Our study results are consistent with the findings reported by Turitz et al.’s cross-sectional study122 
and Nelson et al.’s prospective cohort study.98 Furthermore, the latest phase 3B RCT  of 17-OHPC 
(PROLONG, NCT01004029) was completed in 2018, which did not demonstrate a statistically 
difference in the incidence of PTB between the treatment and placebo group (p=0.72).101,102 The 
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researchers indicated that additional subgroup analyses of the PROLONG data were going to be 
conducted, especially focusing on patients with the highest risk of preterm delivery.102  
However, a few previous studies showed the efficacy of 17-OHPC in preventing PTB or 
prolonging pregnancy duration. One probable reason for the contradiction is that patients using the 
drug, and especially those who were adherent to the drug, may have been at a higher risk of PTB 
than other patients, but the covariates available in the DRG database could not be used to determine 
the level of risk in order to control for it. DeNoble et al. found that patients who initiated prenatal 
care earlier in pregnancy, whose earliest prior PTB occurred at an earlier gestational age, and who 
experienced more PTBs were more likely to use 17-OHPC. Patients with these characteristics may 
be at a higher risk; however, these variables were unavailable in the claims database, so they could 
not be assessed. Our study was also limited to examining the incidence of PTB as the outcome of 
17-OHPC; the gestational duration was not available and thus could not be evaluated. Among 
studies evaluating the effectiveness of 17-OHPC by examining the duration of pregnancy, even 
though they reported a longer gestational duration in the treatment group, women in that group 
may still experience PTB according to the definition of PTB (<37 weeks of gestation). For example, 
Bastek et al. reported the gestational duration of 33.1 weeks in the treatment group versus 31.6 
weeks in the control group.123 Thus, if the rates of PTB were evaluated in these studies as the 
outcome of 17-OHPC, they may find no significant difference in PTB rate between two groups. 
From this perspective, although the promotion of the utilization of 17-OHPC has been 
ongoing, uptake by prescribers may be slow because the effectiveness of 17-OHPC for prevention 
of SPTB reported by observational studies is still controversial, plus the newest clinical trial 
showed no efficacy of 17-OHPC. Thus, more studies are needed to confirm if 17-OHPC is effective 
in preventing recurrent SPTB, and clinicians should be cautious when prescribing 17-OHPC.  
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5.3.4 Objective 7: 17-OHPC Utilization and Incidence of Diabetes or Hypertension 
The utilization of 17-OHPC was not found to be associated with the incidence of diabetes 
(including GDM) in this study. A similar result was observed in Texas Medicaid cohorts (p=0.70) 
(See Appendix Table A.6). The consistent result was also reported in a clinical trial conducted by 
Rouholamin et al.130 Gyamfi et al. also arrived at a similar conclusion. They conducted a secondary 
analysis of 2 double-blind RCTs with 441 patients having singleton and 653 having twin gestations, 
and no association was found in either singleton or twin pregnancies.128  
Although some studies found an association between 17-OHPC and a higher risk for GDM, 
we need to note the difference in patients’ characteristics. Egerman et al. indicated that “in obese 
women with age greater than 35 years, earlier initiation of 17-OHPC may increase the risk for 
GDM.”129 Rebarber et al. found that for patients with similar maternal BMI and age, the incidence 
of GDM was higher for women receiving 17-OHPC.125 However, a commentary relating to this 
article was published and pointed out that some covariates (e.g., ethnicity) were not considered in 
this study. In addition, selection bias may have existed since no explanation was given of the 
criteria used to select women for treatment.140 It is also noteworthy that the two studies reporting 
the positive association were observational studies, while the studies reporting no association were 
conducted based on clinical trial data. Thus, it is possible that some covariates were unavailable 
or not controlled in the observational studies. This limitation commonly exists in retrospective 
cohort studies, which may weaken the strength of conclusions.  
As for the relationship between 17-OHPC utilization and the incidence of hypertension 
(including GHT and preeclampsia), although the Makena billing guide listed GHT and 
preeclampsia as possible maternal complications of Makena based on the results from a clinical 
trial (8.8% in the treatment group versus 4.6% in the control group),75,99 our results showed patients 
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receiving 17-OHPC were less likely to be newly diagnosed with hypertension (p=0.01), though 
the difference was not observed between adherers and non-adherers (p=0.62). This is consistent 
with results reported by Sammour et al.131 and Amaral et al.,133 which were mentioned in the 
literature review. However, no significant difference was observed in Ngai et al.’s study132 and the 
Texas Medicaid cohorts, though both showed the incidence rate of hypertension was lower among 
users compared with non-users (Appendix Table A.6). Thus, whether 17-OHPC can be used for 
GHT or preeclampsia treatment or not still needs to be further confirmed by large scale clinical 
trials and more studies. 
5.4 Study Strengths and Limitations 
5.4.1 Study Strengths 
This study used a nationwide claims database to investigate the utilization, adherence, and 
effectiveness of 17-OHPC. As pointed out in the literature review, most published research with 
similar aims as this study was either prospective cohort research or retrospective research based 
on one state Medicaid claims database or the electronic medical records (EMR) database of a single 
medical institution, where the sample size was usually small (less than 500) and the 
generalizability of the results was limited. In contrast, the sample size of this study was large, and 
the sample included women from different geographic regions. Thus, the results are more 
generalizable. Additionally, the utilization rate by geographic region can be compared.  
Secondly, this study covered a 6-year timeframe (Jan 1st, 2012 – Dec 31st, 2017), which is 
a longer study period than that of other studies (usually 2-3 years), and this makes it feasible to 
examine the utilization trends of 17-OHPC over multiple years.  
Thirdly, a reasonable approach of adherence evaluation was applied in this study, by 
referring to the guidelines and literature and using different methods of adherence measurement. 
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Sensitivity analysis using two methods of estimating medication adherence was conducted in the 
study. 
Lastly, the available covariates were used to control for confounders when evaluating the 
association between utilization and adherence status of 17-OHPC and incidence of SPTB. 
5.4.2 Study Limitations 
This was a retrospective cohort study using the DRG claims database, so the research scope 
is limited by the information provided in the database. Inaccurate and inappropriate coding 
problems caused by human error may limit the accuracy of the research results. These limitations 
should be kept in mind when interpreting the results. 
In objective 2, the specific codes for pharmacy-compounded 17-OHPC were not available, 
so only patients receiving FDA approved 17-OHPC were considered to be 17-OHPC users. Thus, 
the utilization rate of 17-OHPC may be underestimated. In addition, for objective 2 and objective 
4, some patients’ characteristics that may affect the utilization and adherence of 17-OHPC were 
not included in the claims database. For example, records of race were missing for more than 60% 
of the patients, so race differences in 17-OHPC utilization and adherence were not compared. 
Other important characteristics that may affect the chance of receiving and being adherent to 17-
OHPC (e.g., BMI, number of prior PTBs, number of prior term births, gestational age at initiation 
of prenatal care, gestation duration of the prior PTB) were not available in the DRG database. For 
objective 2b and 4b, differences in patients’ insurance types were compared between women with 
and without 17-OHPC, and between adherers and non-adherers. It is possible that some patients 
were covered by more than one insurance plan type (e.g., Medicaid and Blue Cross Blue Shield). 
If a patient was enrolled in both Medicaid and a commercial insurance plan, her insurance type 




As for the medication adherence assessment in objective 3, home injections of 17-OHPC 
cannot be confirmed in the database, so the analysis of adherence was limited to those who 
received in-office injections, which may result in the underestimation of adherence rates. 
When evaluating the outcome of 17-OHPC in objective 6, the duration of pregnancy was 
intended to be used to measure the effectiveness of 17-OHPC. However, women may not see a 
practitioner early in their pregnancy, and it was impossible to obtain their pregnancy dates from 
the claims databases, so we were unable to evaluate the patients’ duration of pregnancy as an 
outcome of 17-OHPC. Patients may get their first high-risk pregnancy diagnosis at any time during 
their gestation, so it is also inappropriate to use the index date as the proxy for the date of becoming 
pregnant. Thus, only the incidence of PTB (yes or no) was used as the outcome to evaluate the 
effectiveness of 17-OHPC. In addition, almost half of the patients’ records of delivery date were 
“NULL/Missing,” due to miscarriage, abortion, missing data, or other reasons. As a result, only 
women with delivery date records were included to assess the outcome of 17-OHPC, which may 
result in overestimation of the effectiveness of 17-OHPC. Simultaneously, some covariates 
indicating women might be at a higher risk of PTB were not available and unable to be controlled 
for in the analysis, and the women at a higher risk may be more likely to use 17-OHPC, so the 
effectiveness of 17-OHPC may be underestimated.  
In objective 7, we explored whether the use of 17-OHPC was associated with the incidence 
of diabetes (including GDM) or hypertension (including GHT and preeclampsia). Patients with an 
initial diagnosis date of diabetes or hypertension before and after their first injection of 17-OHPC 
needed to be separated. However, for the non-user group, the first 17-OHPC injection date did not 
exist. Thus, the index date (diagnosis of risk of PTB) was used as the proxy date of the first 
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injection date of 17-OHPC, given that over 95% of included patients received their first injection 
on the index date. What is more, GDM and diabetes, as well as GHT and hypertension, should be 
better differentiated in this case. However, the DRG database contained both ICD-9-CM and ICD-
10-CM codes. Although ICD-10-CM data provide individual codes for GDM and GHT, ICD-9-
CM data only has codes for “diabetes complicating pregnancy, childbirth, or the puerperium, 
delivered, antepartum condition” and “hypertension complicating pregnancy, childbirth, or the 
puerperium, delivered, antepartum condition,”141 without specific codes for GDM and GHT. Thus, 
the association between 17-OHPC utilization and incidence of GDM, GHT, or preeclampsia could 
not be assessed, but instead the association between 17-OHPC utilization and incidence of diabetes 
(including GDM) and hypertension (including GHT and preeclampsia) were examined in this study. 
In addition, it was assumed that patients without diagnosis codes of diabetes or hypertension during 
the pre-index period did not have the disease, so some patients with pre-index diabetes or 
hypertension might not have been identified if they had either diagnosis more than 6-months 
previously. 
5.5 Conclusions and Recommendations for Future Research 
5.5.1 Conclusions 
To conclude, 17-OHPC utilization showed an increasing trend from 2012 to 2017, but it is 
still underutilized. The insurance type and geographic region were associated with the use of 17-
OHPC. Patients with commercial insurance and patients residing in the Southwest region of the 
U.S. were more likely to use 17-OHPC. The adherence of 17-OHPC was low. No significant 
difference in adherence rate was found among women with different age groups, CCI, 
comorbidities (diabetes and hypertension), or abuse of alcohol, tobacco, or drugs. The SPTB rate 
was not found to be associated with utilization and adherence status of 17-OHPC. In terms of the 
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association between 17-OHPC and maternal complications, the use of 17-OHPC was not 
associated with GDM. However, the use of 17-OHPC was shown to be associated with a lower 
incidence of GHT or preeclampsia. Nonetheless, this may not indicate a ‘practical’ difference from 
the clinical point of view.  
Since the effectiveness of 17-OHPC for prevention of SPTB is still being debated, more 
studies are needed to confirm if 17-OHPC is effective in preventing recurrent SPTB, and 
specifically identify women who are at a higher risk and possibly more likely to benefit from 17-
OHPC.  
5.5.2 Recommendations for Future Research 
In the future, more research is needed to confirm the effectiveness of 17-OHPC in 
preventing SPTB and identifying specific populations that more likely to benefit from 17-OHPC. 
As for investigations of effectiveness of 17-OHPC in real-world settings, large-scale multicenter 
prospective studies, or retrospective studies using EMR databases are recommended for future 
research in order to obtain variables related to pregnancy history and specific gestational age, 
which are usually not available in claims databases, but essential in order to determine a woman’s 
risk level of having a PTB. Thus, it is important to control for these covariates when evaluating 
the effectiveness of 17-OHPC in observational studies.  
A universal approach to evaluate the adherence of 17-OHPC is needed to ensure the 
comparability of results from different studies. What is more, as mentioned in the above limitations 
section, home injections of 17-OHPC were not coded in the DRG database, which should be taken 
into consideration when assessing adherence in the future. The factors related to 17-OHPC 
utilization and adherence should also be explored further by qualitative studies or studies with 




Lastly, although the use of 17-OHPC was found to be associated with a lower incidence of 
hypertension (including GHT and preeclampsia), only a few of studies investigating this 
association were identified, and some of them were experiments on rats. Thus, whether 17-OHPC 
can be used as an option for preeclampsia treatment or prevention still needs to be investigated 







Figure A.1 Patient attrition process for Texas Medicaid databases 
 
 
  13,009 patients had a history of PTB 
11,456 women age >16 and <50 
5,149 women had their index date after 
8/1/2013  
4,500 women had singleton gestations 
14 women had short cervix, cervix 
incompetence or cerclage 
 
3,541 women were eligible to receive 
17-OHPC with delivery date 
 
4,954 women did not have claims 
recorded between 3 and 9 months post 
the index date 
585 women used 17-OHPC 
1,553 women missed age, or age <16 
or >50 
1,353 women had their index date 
during 7/1/2013-7/31/2013 
2,956 women did not use 17-OHPC 
6,502 women had delivery outcome 
recorded between 3 and 9 months post 
the index date 
 
649 women had multiple gestations 
4,486 women had singleton gestations 
without short cervix 
945 women did not have singleton live 




Table A. 1 Comparison of Age by Utilization Status of 17-OHPC in Texas Medicaid Databases 
 Non-17-OHPC Users 
(N, %) 
N=2,956 




Age group   0.39 
16-24 1,261 (84.57) 230 (15.43)  
25-29    848 (83.30) 179 (16.70)  
30-34    622 (82.38) 133 (17.62)  
 35    225 (81.23)   52 (18.77)  
a p values were determined by cross-tabulations with chi square analysis, significant at p<0.05  
 
Table A. 2 Comparison of Race/Ethnicity by Utilization Status of 17-OHPC in Texas 
Medicaid Databases 
* Records of race/ethnicity were missing for 2,306(65.12%) patients 
a p values were determined by cross-tabulations with chi square analysis, significant at p<0.05  
 
Table A. 3 Comparison of Age by Adherence of 17-OHPC in Texas Medicaid Databases 
a p values were determined by cross-tabulations with chi square analysis, significant at p<0.05 
 
  
 Non-17-OHPC Users 
(N, %) 
N=1,008 




Race/Ethnicity   0.14 
White 162 (83.94)   31 (16.06)  
Black 315 (84.00)   60 (16.00)  
Hispanic 531 (79.61) 136 (20.39)  







Age group   0.19 
16-24 193 (83.91) 37 (16.09)  
25-29 135 (79.41) 35 (20.59)  
30-34 101 (75.94) 32 (24.06)  
 35   45 (24.06)   7 (13.46)  
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Table A. 4 Comparison of Race/Ethnicity by Adherence of 17-OHPC in Texas Medicaid 
Databases 
 
* Records of race/ethnicity were missing for 2,306(65.12%) patients 
a p values were determined by cross-tabulations with chi square analysis, significant at p<0.05 
 
Table A. 5 Comparison of PTB Rate by Utilization and Adherence Status of 17-OHPC in 
Texas Medicaid Databases   
PTB Non-17-OHPC 











No 2,172 (73.48) 324 (68.35) 69 (62.16) 0.003 
Yes    784 (26.52) 150 (31.65) 42 (37.84)  
a p values were determined by cross-tabulations with chi square analysis, significant at p<0.05 
 
Table A. 6 Relationship Between 17-OHPC Utilization and Incidence of Diabetes or 










Diabetesb   0.70 
No 1,313 (96.47) 239 (95.98)  
Yes    48 (3.53)            10   (4.02)  
Hypertensionc   0.87 
No 1,170 (85.97) 215 (86.35)  
Yes    191 (14.03)   34 (13.65)  
* Two months pre-index period was applied, so the sample size changed 
a p values were determined by cross-tabulations with chi square analysis, significant at p<0.05 
b Gestational diabetes was included 














Race/Ethnicity   0.69 
White   24 (77.42)   7 (22.58)  
Black   49 (81.67) 11 (18.33)  
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